HYPERBRANCHED DEXTRIN FOR TOPICAL USE IN THE PREVENTION OR TREATMENT OF AT LEAST ONE SYMPTOM OF SKIN INFLAMMATION - Patent application

Abstract

The present invention relates to hyperbranched dextrins, preferentially hyperbranched and hydrogenated dextrins, for topical use in the prevention or treatment of at least one symptom selected from redness, heat, swelling and pain, as well as in the prevention or treatment of symptoms of skin and mucosal inflammation. The present invention also relates to the use of these hyperbranched, preferably hyperbranched and hydrogenated dextrins, for preventing or reducing or eliminating irritation induced by ingredients contained in cosmetic or dermatological compositions.

Description

[Technical field]

[0001] The present invention relates to hyperbranched dextrins, preferentially hyperbranched and hydrogenated dextrins, for topical use in the prevention or treatment of at least one symptom selected from redness, heat, swelling and pain, as well as in the prevention or treatment of symptoms of skin and mucous membrane inflammation. The present invention also relates to the use of these hyperbranched dextrins, preferentially hyperbranched and hydrogenated dextrins, for preventing or reducing or eliminating irritation induced by ingredients contained in cosmetic, dermatological or other compositions. [Background technology]

[0002] The skin is a living anatomical barrier and an exchange zone between the body and its environment, the effectiveness of which determines the maintenance of a good homeostatic balance. The skin comprises a superficial layer consisting of the epidermis, and a deeper layer forming the dermis and subcutaneous tissue. Each of these layers has specific properties that allow the skin to react and adapt to the conditions of its environment.

[0003] The mucous membrane, which forms the object of this application, is the membrane that lines the internal cavities of the body, selected from the mouth and the genitals. This lining is a stack of cells called epithelium. This epithelium gets its name because it contains specific cells that produce mucus. This mucus lubricates and protects the organs that it lines. The mucous membrane plays a protective role and is connected to the skin. Therefore, inflammation of the mucous membrane, mucosal folds or mucosal lesions may sometimes be observed.

[0004] As the body's protective barrier, the skin and mucous membranes are exposed to a wide range of insults that can result in discomfort or, in cases of very intense or more severe reactions, even inflammation of the skin or mucous membranes.

[0005] Skin inflammation can be induced by skin irritation, which occurs especially when the skin comes into contact with irritants such as chemicals, like cleaning agents, or with mechanical actions such as shaving, scrubbing, peeling, or depilation. Skin irritation can also be caused by the effects of temperature, weather, ultraviolet radiation, or even air pollution.

[0006] Irritation of mucous membranes, such as the buccal mucosa, can also be triggered, for example, by certain foods or drinks that lead to the formation of oral ulcers, or by friction, such as brushing with a toothbrush. The genital mucosa can also be locally irritated after repeated rubbing, overly aggressive soaps, too many eggs, very frequent intercourse on a slightly dried mucosa, or an unbalanced microflora.

[0007] These irritants cause irritation of the skin or mucous membranes and activate an innate immune response, the first stage of which is inflammation of the irritated tissue or mucous membrane. Inflammation of the skin or mucous membranes can also be caused by pathologies involving inflammatory processes.

[0008] The action of irritating chemicals depends on their ability to penetrate the stratum corneum, the upper layer of the skin, which acts as a protective barrier. As far as mucous membranes are concerned, the penetration of irritating chemicals is much easier, since mucous membranes do not have a physical barrier made of keratinocytes, but are simply made of non-keratinized epithelial cells through which substances can easily penetrate. When the skin barrier is breached or an irritant penetrates the mucous membrane, the irritant then comes into contact with living cells, interacts with endogenous substances naturally present therein, and thus disrupts the biological function of skin or mucous membrane cells, or even causes tissue damage. The first biological response is an acute inflammatory reaction in the cells of damaged tissue. This reflects the cellular defense against the invading product, to accelerate its elimination based on the innate immune response.

[0009] Irritant substances cause reversible skin damage. By applying them directly to the epidermal surface, their irritant potential can be evaluated through various parameters, such as the expression levels of key biomarkers that play a role in skin inflammation.

[0010] The inflammatory phenomenon is composed of four symptoms: pain, heat, redness, and tissue swelling. Its intensity is proportional to the degree of stimulation (a dose-dependent response) and to the amount of cytokines produced by epidermal keratinocytes to induce and control the initial inflammatory response. Cytokines with a major role in the inflammatory cell response are interleukins IL-1α, IL-6, and IL-8, as well as tumor necrosis factor α (TNF-α). IL-1β, IL-8, RANTES, and VEGF are also biomarkers of inflammation.

[0011] There is a continuing need for new agents of natural or plant origin that can prevent or effectively treat symptoms selected from redness, heat, pain, and swelling, and that can prevent or effectively treat inflammation of the skin or mucous membranes.

[0012] In addition, compounds known to irritate the skin, such as, for example, oxidation products used to dye hair, abrasive products such as synthetic microplastics, mineral powders or pigments in cosmetic creams, surfactants and solvents used in washing or cleansing compositions, acids such as salicylic acid used in peeling, compositions for exfoliating the skin or promoting cell regeneration, or retinoids used in anti-aging compositions, are generally used in low doses.However, even small amounts of these compounds can cause irritation to sensitive skin.

[0013] Thus, there is also a need to identify compounds that can prevent or reduce or eliminate the irritating effects of ingredients, particularly ingredients contained in topical compositions for cosmetic, dermocosmetic, dermatological, pharmaceutical, medical, veterinary, or household use. Summary of the Invention

[0014] Using a two-dimensional reconstructed human epidermis model, the applicant has demonstrated that the hyperbranched hydrogenated dextrins according to the invention induce a reduction in four biomarkers involved in inflammation (IL-1α, IL-1β, RANTES and VEGF).

[0015] Assays of the inflammatory markers IL-1α and IL-8 following inflammation with sodium lauryl sulfate (SLS) in a 0.5% aqueous solution over a 6-hour period showed an action profile of hyperbranched hydrogenated dextrin similar to that of betamethasone 0.05%, the reference positive control for anti-inflammatory effects.

[0016] Following these results, further studies revealed additional biomarkers of inflammation that were also influenced by the treatment administered.

[0017] In this follow-up study, the IL-1α assay confirmed the results obtained previously. Indeed, the overexpression of IL-1α during treatment with SLS was compensated by treatment with hyperbranched hydrogenated dextrin, returning it below the threshold of interleukin overexpression. A reduction in RANTES and VEGF expression was also observed by treatment with hyperbranched hydrogenated dextrin after SLS inflammation. Moreover, IL-1β has also been shown to be underexpressed in the presence of hyperbranched hydrogenated dextrin treatment.

[0018] Thus, for these four biomarkers involved in the mechanisms of inflammation, it was found that treatment with hyperbranched hydrogenated dextrin induced a decrease in these signals.

[0019] The Applicant has also demonstrated that the hyperbranched dextrins according to the invention maintain the integrity of reconstituted human epidermal cell membranes as effectively as betamethasone.

[0020] The Applicant has also demonstrated that application of an aftershave lotion containing hyperbranched and hydrogenated dextrin according to the invention reduced intracellular water loss compared to a placebo lotion.

[0021] Finally, the applicant has shown that the dextrin according to the invention significantly reduces SLS-induced redness as early as 10 minutes compared to the placebo and reference groups, and this reduction is maintained for up to 7 days thereafter. It has also been shown that the dextrin according to the invention significantly reduces transepidermal water loss as early as 30 minutes after application, which then gradually increases over the treatment period of 2 to 7 days, reaching a water loss reduction value that is about 6.6 units greater than the water loss reduction value of the placebo group (i.e., a difference of about 195%). Thus, the dextrin according to the invention helps maintain skin hydration by maintaining the skin's barrier function.

[0022] The present invention therefore relates to hyperbranched dextrins, preferentially hyperbranched and hydrogenated dextrins, for topical use for the prevention or treatment of at least one symptom selected from redness, heat, swelling and pain.

[0023] The present invention also relates to the use of hyperbranched dextrins, preferentially hyperbranched and hydrogenated dextrins, to prevent or reduce or eliminate the irritating effect of ingredients contained in topical compositions for cosmetic, dermocosmetic, dermatological, pharmaceutical, medical, veterinary or household use (e.g. detergents). [Brief description of the drawings]

[0024] [Figure 1] FIG. 1 shows glycosidic bonds that produce non-linear chains. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0025] Hyperbranched dextrin In a first embodiment, the dextrins for therapeutic use that form the object of the present application are hyperbranched dextrins.

[0026] By "dextrins" we mean glucose polymers obtained from granular starch by pyroconversion, in other words by the action of acids on granules in the form of dry solid particles, in a generally dry environment, usually containing residual moisture resulting from physical equilibrium conditions at a given temperature and pressure. Thus, maltodextrins and calcined dextrins, if they are modified to become hyperbranched, fall into the general family of dextrins useful in the present invention.

[0027] In the context of the present invention, by "dextrins", the Applicant also means glucose polymers derived from acid or enzymatic liquefaction or hydrolysis of starch, generally referred to as "maltodextrins", "starch hydrolysates" or "glucose syrups", when these polymers are further chemically or enzymatically modified, in particular by branching enzymes, to present glucosidic bonds between anhydroglucose molecules whose nature differs significantly from that of the starch from which they are derived. Thus, maltodextrins, starch hydrolysates, glucose syrups and calcined dextrins are classified into the general family of dextrins useful in the present invention, since they differ from the starches from which they are derived in terms of glucosidic bonds by the inclusion of "atypical" bonds.

[0028] By "hyperbranched dextrin", the Applicant means a "dextrin" having glucosidic bonds between anhydroglucose molecules which differ significantly in nature and amount from those which naturally constitute the starch from which it is derived. This includes the naturally occurring, but more abundant, glucosidic bonds between anhydroglucose molecules, 1,6 bonds, as well as the glucosidic bonds, 1,3 and 1,2 bonds, which do not naturally occur in starch and are known as "atypical". Thus, a hyperbranched dextrin is a dextrin which contains a large proportion of branched glucosidic bonds relative to the total glucosidic bonds present in said dextrin. The term "hyperbranched" may also be replaced by the term "highly branched".

[0029] "A large proportion" is understood to mean a proportion of branched glucosidic bonds of 5% or more, preferentially 10% or more, more preferentially 20% or more, more preferentially 30% or more, more preferentially 40% or more, more preferentially 50% or more of the total of branched and linear glucosidic bonds. Glucosidic branching bonds are bonds that generate non-linear chains in a proportion higher than normal for native starch. Glucosidic bonds that generate non-linear chains are 1,6, 1,3 and 1,2 glucosidic bonds, as shown in Figure 1 [Figure 1]. 1,3 and 1,2 bonds are atypical glucosidic bonds. The normal values ​​for these bonds in native starch are about 5% for 1,6 bonds and about 0% for 1,2 and 1,3 bonds. The complement is made up of 1,4 glucosidic bonds, i.e. about 95%. 1,4 bonds are bonds that create linear chains.

[0030] For 1,6 glucosidic bonds, the hyperbranched dextrins useful according to the invention are characterized by values ​​of more than 5% for the sum of the 1,2, 1,3, 1,4 and 1,6 bonds, preferentially greater than or equal to 10% for the sum of the 1,2, 1,3, 1,4 and 1,6 bonds, more preferentially greater than or equal to 12% for the sum of the 1,2, 1,3, 1,4 and 1,6 bonds and most preferentially greater than or equal to 15% for the sum of the 1,2, 1,3, 1,4 and 1,6 bonds.

[0031] Thus, according to one embodiment, the hyperbranched dextrin comprises at least 5%, preferentially at least 10%, preferentially at least 12%, preferentially at least 15% 1,6 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds.

[0032] For 1,2 and 1,3 glucosidic bonds, values ​​useful in the present invention are greater than 1% relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds, preferentially greater than or equal to 5% relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds, and more preferentially greater than or equal to 10% relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds.

[0033] Thus, according to one embodiment, the hyperbranched dextrin comprises at least 1%, preferentially at least 5%, preferentially at least 10% and preferentially at least 20% 1,2 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds.

[0034] According to one embodiment, the hyperbranched dextrin comprises at least 1%, preferentially at least 5%, preferentially at least 10% and preferentially at least 20% 1,3 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds.

[0035] For 1,4 glucosidic bonds, values ​​useful in the present invention are less than 90%, preferentially less than 70%, preferentially less than 60%, preferentially less than 50% of the sum of 1,2, 1,3, 1,4 and 1,6 bonds, and preferentially between 42 and 50% of the sum of 1,2, 1,3, 1,4 and 1,6 bonds.

[0036] Thus, according to one embodiment, the branched dextrins contain at most 90%, preferentially at most 70%, preferentially at most 50% 1,4 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds.

[0037] Preferentially, the hyperbranched, preferably hyperbranched and hydrogenated dextrins useful in the present invention have a content of 1,6 glucosidic bonds of between 5% and 40%, preferentially between 10% and 30%, more preferentially between 12% and 22% and most preferentially between 15% and 20%, based on the sum of 1,2, 1,3, 1,4 and 1,6 bonds.

[0038] According to one embodiment, the hyperbranched dextrins, preferably hyperbranched and hydrogenated dextrins, useful in the present invention have, relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds, - up to 90% 1,4 glucosidic bonds, - containing at least 5% 1,6 glucosidic bonds.

[0039] According to one embodiment, the hyperbranched dextrins, preferably hyperbranched and hydrogenated dextrins, useful in the present invention have, relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds, - up to 70% 1,4 glucosidic bonds, - containing at least 5% 1,6 glucosidic bonds.

[0040] According to one embodiment, the hyperbranched dextrins, preferably hyperbranched and hydrogenated dextrins, useful in the present invention are - 5% to 40%, preferentially 10% to 30%, more preferentially 12% to 22% and most preferentially 15% to 20% of 1,6 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; - 42-50% 1,4 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; - 1-20% of 1,3 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; - 1-20% of 1,2 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds.

[0041] According to one embodiment, the hyperbranched dextrins, preferably hyperbranched and hydrogenated dextrins, useful in the present invention are - at least 5%, preferentially at least 10%, more preferentially at least 12% and most preferentially at least 15% 1,6 glucosidic bonds relative to the sum of the 1,2, 1,3, 1,4 and 1,6 bonds; - at most 70%, preferentially at most 60% and most preferentially at most 50% 1,4 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; - at least 1%, preferentially at least 5%, more preferentially at least 10% and most preferentially at least 20% 1,3 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; - have at least 1%, preferentially at least 5%, more preferentially at least 10% and most preferentially at least 20% 1,2 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6.

[0042] According to one embodiment, the hyperbranched dextrins, preferably hyperbranched and hydrogenated dextrins, useful in the present invention are - 5 to 40%, preferentially 10 to 30%, more preferentially 12 to 22% and most preferentially 15 to 20% of 1,6 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; - 42-70%, preferentially 42-60% 1,4 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; - 1-20%, preferentially 1-10%, more preferentially 5-15% and most preferentially 5-10% of 1,3 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds, - having from 1 to 20%, preferentially from 1 to 10%, more preferentially from 5 to 15% and most preferentially from 5 to 10% of 1,2 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds;

[0043] Besides using the well-known thermal conversion processes applied to granular starch to prepare dextrins, in other words the use of acids on granular starch at high temperatures, typically in a dry environment, these starch branch bond contents can also be obtained by the action of so-called "branching" or "rebranching" enzymes on liquefied starches such as maltodextrins, starch hydrolysates or glucose syrups, which are optionally hydrogenated before or afterwards.

[0044] These branch bond contents can therefore be obtained both by the action of so-called "branching" or "rebranching" enzymes on liquefied starch and / or by the action of acids on granular or liquefied starch, typically at high temperature in a drying medium.

[0045] The determination of the content of 1,2, 1,3, 1,4, and 1,6 glucosidic bonds can be carried out using the classical methylation technique described in HAKOMORI, S., 1964, J. Biochem., 55, 205. "A rapid permethylation of glycolipid, and polysaccharide catalyzed by methylsulfinyl carbanion in dimethyl sulfoxide". This method allows the chemical characterization of the glucosidic bonds by distinguishing between free OH groups and the bonded group. It is a destructive method that includes the steps of methylation, hydrolysis, reduction with NaBD4, acetylation, and analysis by mass spectrometry.

[0046] According to one embodiment, the hyperbranched dextrin has a number average molecular weight Mn of less than or equal to 10,000 g / mol, preferentially less than or equal to 4500 g / mol, more preferentially from 1000 to 3500 g / mol, even more preferentially from 1500 to 3500 g / mol and most preferentially from 1800 to 3200 g / mol.

[0047] According to one embodiment, the hyperbranched dextrin has a polymolecularity index (designated IP), which is the ratio of the weight-average molar mass to the number-average molar mass, less than or equal to 15, preferentially less than or equal to 10, more preferentially less than or equal to 5 and most preferentially less than or equal to 3.

[0048] The Mn, Mw and IP values ​​are determined by steric exclusion chromatography, based on the size-selective retention of solute molecules by permeation or non-permeation into the pores of the stationary phase. The size exclusion chromatography columns used were PSS SUPREMA 100 and PSS SUPREMA 1000 connected in series and coupled to a light scattering detector.

[0049] According to one embodiment, the hyper-branched dextrin has a reducing sugar content of less than or equal to 20%, preferentially less than or equal to 15%, more preferentially less than or equal to 10%, even more preferentially less than or equal to 6% and most preferentially less than or equal to 3% relative to the total mass of the hyper-branched dextrin. The reducing sugar content, expressed as glucose, by weight relative to the dry weight of the analyzed product is determined by the Bertrand method.

[0050] According to one embodiment, the hyperbranched dextrins useful for the invention have a relatively high content of residual 1,4 glucosidic bonds. This content of 1,4 glucosidic bonds is between 42 and 50% relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds, in combination with a content of 1,6 glucosidic bonds between 12 and 22% relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds. Preferentially, the hyperbranched dextrins useful for the invention have a 1,4:1,6 glucosidic bond ratio between 1.9 and 4.2, in particular between 2.3 and 3.5.

[0051] According to one embodiment, the hyperbranched dextrins useful for the invention have a content of 1,3 glucosidic bonds of 1 to 10% relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds, in combination with a content of 1,4 glucosidic bonds of 42 to 50% relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds. Preferentially, the hyperbranched dextrins useful for the invention have a 1,4:1,3 glucosidic bond ratio of 0.02 to 0.24, in particular 0.1 to 0.2. According to one embodiment, the hyperbranched dextrins useful for the invention have a content of 1,2 glucosidic bonds of 1 to 10% relative to a content of 1,4 glucosidic bonds of 42 to 50%. Preferentially, the hyperbranched dextrins useful for the invention have a 1,4:1,2 glucosidic bond ratio of 0.02 to 0.24, in particular 0.1 to 0.2.

[0052] According to one embodiment, the hyperbranched dextrins useful in the present invention are - 5% to 40% 1,6 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; - a reducing sugar content of less than 20% based on the total weight of hyperbranched dextrin; - a polymolecularity index of 15 or less; and a number average molecular weight Mn of less than or equal to 4500 g / mol.

[0053] According to one embodiment, the hyperbranched dextrins useful in the present invention are - 10% to 30% 1,6 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; - 42-70% 1,4 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; - a reducing sugar content of less than 10% of the total mass of the hyperbranched dextrin; - a polymolecularity index of 10 or less; and having a number average molecular weight Mn of 1000 to 3500 g / mol.

[0054] According to one embodiment, the hyperbranched dextrins useful in the present invention are - 12% to 22% 1,6 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; - 42-50% 1,4 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; - 1-20% of 1,3 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; - 1-20% of 1,2 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; - a reducing sugar content of less than 6% of the total mass of the hyperbranched dextrin; - a polymolecularity index of 5 or less; and having a number average molecular weight Mn of 1500 to 3000 g / mol.

[0055] Hyperbranched dextrins useful for the present invention are commercially available, such as the "Nutriose® FM 06", "Nutriose® FM 10" and "Nutriose® FM15S" products by Roquette® or the "Promitor® Soluble Fiber" product range by Tate & Lyle.

[0056] Other commercial products available under the name "STA-LITE® Polydextrose" from Tate & Lyle or "Oliggo-fiber®" from Cargill are hyperbranched polysaccharides or oligosaccharides which, as such or after possible hydrogenation, may possibly exhibit soothing properties like hyperbranched dextrins for the purposes of this application.

[0057] Hyperbranched and Hydrogenated Dextrins In a second embodiment, the dextrins useful for non-therapeutic uses forming the object of the present application are hyperbranched and hydrogenated dextrins. Such dextrins can be obtained by subjecting hyperbranched dextrins according to the object of the present application to hydrogenation or by applying a "branching" or "rebranching" process to previously hydrogenated dextrins. Hydrogenation can be achieved, for example, by subjecting an aqueous solution of hyperbranched dextrin to hydrogen gas in the presence of a catalyst such as Raney nickel.

[0058] Thus, an additional feature may be advantageously added to the above-mentioned embodiment relating to hyperbranched dextrins, namely a reducing sugar content of less than or equal to 5% by weight, preferentially less than or equal to 3% by weight, more preferentially less than or equal to 2% by weight, more preferentially less than or equal to 1% by weight, more preferentially less than or equal to 0.5% by weight and most preferentially less than or equal to 0.15% by weight.

[0059] According to one embodiment, the hyperbranched and hydrogenated dextrins useful in the present invention are - 5% to 40% 1,6 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; - a reducing sugar content of less than 4% based on the total weight of hyperbranched dextrin; - a polymolecularity index of 15 or less; and a number average molecular weight Mn of less than or equal to 4500 g / mol.

[0060] According to one embodiment, the hyperbranched and hydrogenated dextrins useful in the present invention are - 10% to 30% 1,6 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; - 42-70% 1,4 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; - a reducing sugar content of less than 3% based on the total weight of hyperbranched dextrin; - a polymolecularity index of 10 or less; and having a number average molecular weight Mn of 1000 to 3500 g / mol.

[0061] According to one embodiment, the hyperbranched and hydrogenated dextrins useful in the present invention are - 12% to 22% 1,6 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; - 42-50% 1,4 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; - 1-20% of 1,3 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; - 1-20% of 1,2 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; - a reducing sugar content of less than 2% based on the total weight of hyperbranched dextrin; - a polymolecularity index of 5 or less; and having a number average molecular weight Mn of 1500 to 3000 g / mol.

[0062] Hyperbranched and hydrogenated dextrins useful in the present invention are commercially available, such as "Nutriose® HM 06" by Roquette.

[0063] Biomarkers involved in inflammation (IL-1α, IL-1β, RANTES, and VEGF) Inflammation is essentially an innate self-protective immune response to harmful stimuli, especially infectious agents and physical or chemical attacks. It is a temporal regulation and adaptive modification of cellular functions to return to a pre-invasion state if possible. The temporal expression profile of cytokines in epidermal keratinocytes is important in modulating the inflammatory response (Kataru et al., 2009). IL-1, 6, 8, and TNF-α are known to be potent inducers of keratinocyte-derived VEGF (Detmar et al., 1995).

[0064] IL-1 is an essential pro-inflammatory cytokine that mediates the acute phase of inflammation by inducing local and systemic responses. IL-1α functions as an "alarm signal." During necrotic cell death, IL-1α is released into the extracellular space where it stimulates chemokine production, leading to infiltration by neutrophils and then monocytes. IL-1α is constitutively present in various epithelial cell types in healthy subjects, whereas IL-1β is predominantly induced under pathological conditions.

[0065] The mediators RANTES and VEGF are connective tissue and vascular growth factors.

[0066] RANTES has been shown to induce endothelial cell spreading and migration and participate in the formation of vascular networks through VEGF secretion. VEGF is an important mediator of skin angiogenesis and vascular permeability, which is involved in physiological processes such as wound repair and hair growth, as well as pathological conditions including skin inflammation, skin cancer, and psoriasis. In many skin conditions such as psoriasis, contact dermatitis, wound healing, and skin neoplasms, which are closely related to angiogenesis or chronic inflammation, there is a significant induction of VEGF in epidermal keratinocytes, suggesting that increased VEGF plays an important role in these skin problems.

[0067] The RANTES chemokine is a chemoattractant for eosinophils, memory phenotype T lymphocytes, and monocytes, and plays an important role in chronic inflammatory and allergic diseases.

[0068] Advantageously, for these four biomarkers involved in the mechanisms of inflammation, IL-1α, IL-1β, RANTES, and VEGF, it was found that treatment with hyperbranched dextrins induced a decrease in these signals.

[0069] From these results we can conclude that hyperbranched, preferentially hyperbranched and hydrogenated dextrins are effective in the prevention or treatment of at least one symptom selected from redness, heat, swelling and pain, as well as in the prevention or treatment of skin inflammation and mucous membrane inflammation.

[0070] Redness, heat, swelling, pain The present invention relates to a hyperbranched, preferentially hyperbranched and hydrogenated dextrin for use in the prevention or treatment of at least one symptom selected from redness, heat, swelling and pain.

[0071] Prevention of at least one symptom selected from redness, heat, swelling, and pain means preventing the onset of at least one of these symptoms, as well as delaying the onset of at least one of these symptoms, and preventing the worsening of at least one of these symptoms.

[0072] Treatment of at least one symptom selected from redness, heat, swelling, and pain means elimination of at least one of the symptoms, or at least a reduction in the intensity of at least one of the symptoms, e.g. a reduction in the intensity of redness and / or heat and / or swelling and / or pain.

[0073] epithelial tissue According to one embodiment, the at least one condition is located in at least one epithelial tissue selected from keratinizing multilayered squamous epithelium, non-keratinizing multilayered squamous epithelium, stratified columnar epithelium, ciliated or non-ciliated pseudostratified columnar epithelium.

[0074] The epidermis is a multilayered keratinized squamous epithelium.

[0075] The oral, vaginal, and urogenital mucosa are non-keratinizing, multilayered squamous epithelium.

[0076] The nares and conjunctival fornix are stratified columnar epithelium.

[0077] The nasal mucosa is a ciliated or non-ciliated pseudostratified columnar epithelium.

[0078] Thus, according to one embodiment, the at least one pathology is located in the epidermis or the oral or vaginal mucosa or the nasal passages or the conjunctival cul-de-sac or the nasal mucosa.

[0079] According to one embodiment, the at least one symptom is located in the epidermis, preferentially in the epidermis of the skin or scalp.

[0080] According to one embodiment, the epidermis of the skin or scalp is a sensitive epidermis.

[0081] skin inflammation Cutaneous inflammation is understood to mean the presence of four symptoms on the epidermis: redness, heat, swelling and pain.

[0082] The epidermis is preferentially the epidermis of the skin or scalp.

[0083] According to one embodiment, the epidermis is a sensitive epidermis.

[0084] Skin inflammation is also known as dermatitis.

[0085] Thus, according to one embodiment, the present invention relates to hyperbranched dextrins, preferentially hyperbranched and hydrogenated dextrins, for topical use in the prevention or treatment of inflammatory skin conditions.

[0086] For purposes of the present invention, "topical use" means use on a body surface such as the skin or mucous membranes.

[0087] Preventing the symptoms of skin inflammation means not only preventing the onset of the four symptoms of skin inflammation, but also delaying the onset of the four symptoms of skin inflammation and preventing the aggravation of the four symptoms of skin inflammation.

[0088] Treating the symptoms of skin inflammation means elimination of the four symptoms of skin inflammation or at least a reduction in the intensity of the four symptoms of skin inflammation, for example a reduction in the intensity of redness and heat and swelling and pain.

[0089] Non-pathological causes There are many causes for the appearance of one or all of the symptoms selected from redness, heat, swelling, and pain.

[0090] Thus, at least one symptom is induced by at least one of the following conditions: infectious agents, chemicals, ingredients contained in a topical composition for cosmetic, dermocosmetic, dermatological, pharmaceutical, medical, veterinary, or household use (e.g., detergents), mechanical insults, environmental agents, thermal insults, food and beverages. Another non-pathological cause may be an oral or intravenous therapeutic treatment that produces one or more secondary skin reactions.

[0091] Infectious agents include bacteria, yeasts, molds, parasites, viruses, as well as mites, lice, and insects when they attack the skin through stings or bites. Examples include dry patches caused by parasites.

[0092] Mechanical aggressions include rubbing, brushing, shaving, cutting, micro-cuts, physical aggression, depilation, polishing, scrubbing, frequent washing, hard water containing high concentrations of limestone, etc.

[0093] Friction can be caused by clothing rubbing against the skin or skin rubbing against skin. For example, clothing made of wool or tight fitting clothing worn in contact with the skin, such as socks or scarves, can rub against the skin and thus cause skin irritation. Friction can also be caused by the prolonged wearing of helmets, masks, especially surgical masks, protection against weather, protection against microorganisms such as bacteria or viruses, protection against chemicals or solvents, or protection against dust.

[0094] Abrasive means contacting the skin or mucosa with an abrasive, i.e. solid particles that are generally irregularly shaped and not smooth. For skin, abrasives include gravel, sand, and magnesia. For oral mucosa, abrasives may include calcium carbonate.

[0095] Brushing refers to the action of the brush, specifically the action of the toothbrush against the gums.

[0096] Environmental factors include pollution, exposure to sunlight, radiation such as X-rays and UV rays, cold, wind, dryness, humidity, and the like.

[0097] Thermal insults include overexposure to sunlight or exposure to hot or cold sources.

[0098] Foods and beverages include spices, dairy products, dried fruits, nuts, pineapple, acidic foods, vinegar, alcohol, etc.

[0099] Chemicals include irritants and pollutants such as detergents, pollutants, cigarette smoke, household products, and especially household cleaners.

[0100] Ingredients contained in topical compositions for cosmetic, dermocosmetic, dermatological, pharmaceutical, medical, veterinary, or household use include cosmetic actives, dermatological actives, surfactants, solvents, preservatives, fragrances, acids, stripping agents, and detergents.

[0101] These active ingredients with irritating capabilities are described in document FR 2 902 998. Examples of dermatological or cosmetic active ingredients thus include certain desquamating agents, which may also be peeling agents.

[0102] Specific exfoliants include abrasive / exfoliating particles derived from mineral, organic, natural, or synthetic sources. Of particular note are pumice particles, silica, polyethylene beads, nylon, and fruit kernel powders.

[0103] Among these desquamating agents, the following are likely to cause skin irritation: saturated and unsaturated monocarboxylic acids (acetic acid), saturated and unsaturated dicarboxylic acids, saturated and unsaturated tricarboxylic acids; monocarboxylic alpha-hydroxy acids and beta-hydroxy acids; dicarboxylic alpha-hydroxy acids and beta-hydroxy acids; tricarboxylic alpha-hydroxy acids and beta-hydroxy acids; polycarboxylic acids, polyhydroxymonocarboxylic acids, polyhydroxybicarboxylic acids, polyhydroxytricarboxylic keto acids, alpha-keto acids, and beta-keto acids.

[0104] Of particular note among the α-hydroxy acids or their esters are: glycolic acid, diacids such as octadecenedioic acid, citric acid, lactic acid, tartaric acid, malic acid or mandelic acid, their esters such as dialkyl tartrates (C12-C13), branched C12-13 tri-alcohol citrates.

[0105] Among the beta-hydroxy acids are salicylic acid and its derivatives, including n-octanoyl-5-salicylic acid.

[0106] Examples of α-keto acids include ascorbic acid and its derivatives.

[0107] Other desquamating agents include: pyruvic acid, gluconic acid, glucuronic acid, oxalic acid, malonic acid, succinic acid, acetic acid, gentisic acid, cinnamic acid, azelaic acid; phenol; resorcinol; urea and its derivatives, hydroxyethyl urea; oligofucose; jasmonic acid and its derivatives; ascorbic acid and its derivatives, trichloroacetic acid; Saphora japonica extract and resveratrol.

[0108] From the desquamating agents, those capable of acting on enzymes involved in desquamation or corneodesmosome degradation may also be more likely to cause skin irritation.

[0109] These include inorganic salt chelating agents such as EDTA; N-acyl-N,N',N'-ethylenediaminetriacetic acid; aminosulfone compounds, and specifically (N-2 hydroxyethylpiperazine-N-2-ethane)sulfonic acid (HEPES); 2-oxothiazolidine-4-carboxylic acid derivatives (procysteine); glycine-type alpha-amino acid derivatives; honey; sugar derivatives such as O-octanoyl-6-D-maltose, O-linoleyl-6-D-glucose, and N-acetylglucosamine.

[0110] Retinoids are also compounds that can cause skin irritation. Examples include retinol and its esters, retinal, 30 retinoic acid and its derivatives, and adapalene.

[0111] Salts and derivatives of the above-mentioned compounds, such as cis or trans forms, racemic mixtures, dextrorotatory or levorotatory forms, are also considered to be compounds likely to cause skin irritation.

[0112] Other dermatological or cosmetic active ingredients that have a high potential to cause skin irritation are also listed below: urea and its derivatives, for example hydroxyethylurea, - certain vitamins, such as vitamin D and its derivatives, for example vitamin D3, vitamin D2, calcitriol, calcipotriol, tacalcitol, 24,25-diOH vitamin D3, 1-OH vitamin D2, and 1,24-diOH vitamin D2; vitamin B9 and its derivatives; peroxides, such as benzoyl peroxide and hydrogen peroxide, hair loss inhibitors, such as minoxidil and its derivatives, e.g. Aminxil; hair dyes and colorants, for example aminophenols and their derivatives, such as para-phenylenediamine (p-PDA), N-phenyl p-PDA, toluene-2,5-diamine sulfate, meta-phenylenediamine (m-PDA), toluene-3,4-diamine, and ortho-phenylenediamine (o-PDA); antiperspirants such as aluminium salts, e.g. aluminium hydroxychloride, - Deodorant, hair removal and / or perm active ingredients, such as thioglycollate and ammonia, -Thioglycolate and its salts, -Phenoxyethanol, 1,2-pentanediol, - Alcohol fragrance solutions (perfume, eau de toilette, aftershave, deodorant) - Anthralin (dioxyanthranol), - Anthranode - lithium salts, - Bleaching agents (e.g. hydroquinone, high-concentration vitamin C, kojic acid), - Certain slimming active ingredients with a heating effect, - nicotinates and their derivatives, - Capsaicin, an anti-lice active ingredient (pyrethrin), - antiproliferative agents, such as 5-fluorouracil or methotrexate, - antiviral agents, - antiparasitic agents, - antifungal agents, - Antipruritic, - antiseborrheic agents, - Certain sunscreens, - color enhancers, such as psoralens and methylangesilins, and - A mixture of them.

[0113] Preservatives include propionic acid, calcium propionate, formaldehyde, paraformaldehyde, o-phenylphenol or its salts, zinc pyrithione, sodium sulfite, sodium hydrogen sulfite, or sodium pyrosulfite, ammonium, potassium, chlorobutanol, methylparaben, ethylparaben, propylparaben, formic acid and its salts, such as sodium formate, benzoic acid and its salts, such as sodium benzoate, sorbic acid and its salts, such as calcium sorbate, sodium sorbate, potassium sorbate, salicylic acid and its salts, dehydroacetic acid and its salts, such as sodium dehydroacetate, undecylenic acid and its salts, such as calcium undecylenate, and urea. Examples of the antibacterial agents include potassium undecylenate, sodium undecylenate, phenoxyethanol, 1,2-dimethylol-5,6-dimethylhydantoin, benzyl alcohol, chlorhexidine, chlorhexidine diacetate, chlorhexidine digluconate, chlorhexidine dihydrochloride, behentrimonium chloride, cetrimonium chloride, cetrimonium bromide, lauryltrimonium chloride, lauryltrimonium bromide, steartrimonium chloride, steartrimonium bromide, hexamidine, hexamidine diisethionate, chlorphenesin, benzalkonium chloride, benzalkonium bromide, benzalkonium saccharinate, and ethyl lauroyl arginate.

[0114] Surfactants include anionic, cationic, and amphoteric surfactants, more specifically, anionic surfactants, e.g., alkyl sulfates and alkyl ether sulfates, such as lauryl sulfate and lauryl ether sulfate, and their salts, particularly the sodium salts.

[0115] In a preferred embodiment of the present invention, the compound likely to cause skin irritation is selected from surfactants, bases, and acids. The acids may be selected from citric acid, lactic acid, acetic acid, dehydroacetic acid, formic acid, gluconic acid, succinic acid, salicylic acid, glucuronic acid, retinoic acid, glycolic acid, phytic acid, ascorbic acid, and levulinic acid. The bases may be selected from sodium hydroxide, potassium hydroxide, triethanolamine, and aminomethylpropanol.

[0116] Preferentially, at least one symptom selected from redness, heat, swelling and pain is induced by a chemical substance, an ingredient contained in a cosmetic or dermatological preparation, a mechanical insult, a thermal insult, or an environmental factor.

[0117] More preferentially, at least one symptom selected from redness, heat, swelling, and pain or inflammation of the skin is induced by exposure to a chemical selected from surfactants, detergents, hair oxidants or bleaching agents, or an ingredient contained in a topical composition for cosmetic or dermatological use, or is induced by a mechanical insult selected from rubbing, shaving, cutting, micro-cutting, depilation, abrasion, and peeling.

[0118] There are also many non-pathological causes of skin inflammation.Indeed, skin inflammation can be induced by at least one of the causes already described and selected from infectious agents, chemical products, cosmetics, dermocosmetics, ingredients contained in topical compositions for dermatological, medical, pharmaceutical, veterinary or household use, mechanical insults, environmental factors, thermal insults, food and drink, but also by skin irritation, skin corrosion, endogenous skin inflammation, or a combination of these causes.

[0119] Skin irritationSkin irritation includes acute skin irritation (or acute irritant contact dermatitis), cumulative skin irritation (or cumulative irritant contact dermatitis), and phototoxicity (or phototoxic dermatitis).

[0120] "Acute skin irritation" or "acute irritant contact dermatitis" is understood to mean a reversible local inflammatory response of the skin of a normal organism to a direct injury caused by a single application of a toxic substance, without the intervention of immunological mechanisms.

[0121] "Cumulative skin irritation" or "cumulative irritant contact dermatitis" is understood to mean reversible irritation resulting from repeated or continued exposure to substances that do not themselves cause acute irritation.

[0122] "Phototoxicity" or "phototoxic dermatitis" is understood to mean irritation resulting from light-induced molecular changes in the structure of chemicals applied to the skin.

[0123] Thus, according to one embodiment, the skin irritation is selected from cumulative irritant contact dermatitis, acute irritant contact dermatitis, and phototoxic dermatitis.

[0124] In a preferred embodiment, the skin irritation is cumulative irritant contact dermatitis.

[0125] "Dermal erosion" is understood to mean a direct chemical action on normal living skin, which leads to its destruction and irreversible changes at the point of contact. The erosion is manifested as ulceration and necrosis, followed by the formation of a scar.

[0126] According to one embodiment, phototoxicity is induced by chemicals, ingredients contained in topical compositions for cosmetic or dermatological use.

[0127] In preferred embodiments, skin inflammation is induced by exposure to chemicals and ingredients contained in topical compositions for cosmetic or dermatological use, mechanical insults, and thermal insults.

[0128] In a preferred embodiment, skin inflammation is induced by exposure to chemicals and ingredients contained in topical compositions for cosmetic or dermatological use, and preferentially by ingredients contained in topical compositions for cosmetic or dermatological use.

[0129] "Endogenous skin inflammation" is understood to mean inflammation induced by one or more biological factors endogenous to the human organism or by one or more pathogens endogenous to the human organism, in other words by pathogens synthesized by the human organism itself.

[0130] Causes of mucosal inflammation According to one embodiment, the present invention relates to a hyperbranched dextrin, preferentially a hyperbranched hydrogenated dextrin, for use in the prevention or treatment of symptoms of mucosal inflammation.

[0131] According to one embodiment, the inflammation is selected from inflammation of the oral mucosa, preferentially inflammation of the oral mucosa due to anionic surfactants, or inflammation of the oral mucosa due to irritation caused by tooth brushing, which may be applied to the oral mucosa by toothpaste, generally with brushing, or by mouthwash, generally without brushing.

[0132] Thus, according to one embodiment, inflammation of the mucosa is induced by ingredients contained in a topical composition for cosmetic, dermocosmetic, dermatological, pharmaceutical, medical, veterinary, or household use, such as surfactants, or by mechanical insult, such as brushing.

[0133] pathological cause According to one embodiment, the skin inflammation is induced by a dermatological pathology involving an inflammatory process.

[0134] According to one embodiment, the dermatological pathology involving an inflammatory process is selected from psoriasis, cutaneous atopy, atopic dermatitis, immediate hypersensitivity type allergic reactions, delayed hypersensitivity type allergic reactions, post-inflammatory hyperpigmentation, immune dermatoses, solar elastosis, alopecia areata, vitiligo, systemic lupus erythematosus, pemphigus vulgaris, dystrophic epidermolysis, and autoimmune leukoderma, erythema.

[0135] Immediate hypersensitivity-type allergic skin reactions include hives, lucitis (or sun allergy), and allergies due to exposure to detergents.

[0136] Delayed hypersensitivity type allergic skin reactions include contact dermatitis, seborrheic dermatitis, acne, and eczema.

[0137] The erythema can be caused by ultraviolet light, rubbing, or minor cuts.

[0138] According to one embodiment, the atopic dermatitis is atopic dermatitis of sensitive skin.

[0139] Preferentially, the dermatological pathology is selected from erythema, psoriasis, cutaneous atopy, atopic dermatitis, immediate hypersensitivity type allergic reactions, delayed hypersensitivity type allergic reactions, and post-inflammatory hyperpigmentation.

[0140] Preferentially, the erythema is caused by ultraviolet light.

[0141] Preferentially the immediate hypersensitivity type allergic reaction is urticaria.

[0142] Preferentially, the delayed hypersensitivity type allergic reaction is selected from contact dermatitis and eczema.

[0143] According to one embodiment, the mucosal inflammation is induced by a dermatological pathology involving an inflammatory process.

[0144] According to one embodiment, the dermatological pathology is selected from pathologies of the oral mucosa, the vaginal mucosa and the urogenital mucosa, preferentially from pathologies of the oral mucosa.

[0145] According to one embodiment, the oral mucosal pathology is selected from gingivitis, oral lichen planus, oral ulcers, and the like.

[0146] The terms "prevention" or "treatment" or "preventive method" or "treatment method" are not absolute terms but refer to a procedure or plan of action designed to induce an overall beneficial effect, such as disappearance of the pathology, even with a low probability of success, but also to induce a delay in the onset of the symptoms of the pathology, or a reduction in the severity of one or more symptoms. In the case of skin inflammation induced by dermatological pathologies that typically involve inflammatory processes, prevention does not only mean preventing the symptoms of the pathology, but also preventing the symptoms of the pathology from worsening.

[0147] The present invention also relates to a method for the prevention or treatment of symptoms of skin inflammation induced by dermatological pathologies involving inflammatory processes, comprising the administration of hyperbranched dextrins, preferentially hyperbranched and hydrogenated dextrins, to a patient in need thereof.

[0148] The present invention also relates to the use of hyperbranched dextrins, preferentially hyperbranched and hydrogenated dextrins, to obtain a medicament for the prevention or treatment of cutaneous inflammatory symptoms induced by dermatological pathologies involving inflammatory processes.

[0149] The present invention also relates to a composition comprising hyperbranched dextrins, preferentially hyperbranched and hydrogenated dextrins, for therapeutic use in the prevention or treatment of symptoms of skin inflammation induced by dermatological pathologies involving inflammatory processes.

[0150] Preventing and / or reducing the irritating effects of chemicals or ingredients contained in topical compositions for cosmetic, dermocosmetic, dermatological, pharmaceutical, medical, veterinary, or household use According to one embodiment, the present invention relates to the use of hyperbranched dextrins, preferentially hyperbranched and hydrogenated dextrins, to prevent, reduce or eliminate the irritating effect of chemical products that come into contact with the skin and mucous membranes, or of topically applied ingredients contained in topical compositions for cosmetic, dermocosmetic, dermatological, pharmaceutical, medical, veterinary or household use.

[0151] Irritation means the appearance of at least one symptom in epithelial tissue or mucosa selected from redness, heat, swelling, and pain following exposure of the skin or mucosa to one or more chemicals or following topical application of a cosmetic, dermocosmetic, dermatological, pharmaceutical, medical, veterinary, or household composition that contains ingredients that irritate epithelial tissue or mucosa.

[0152] The hyperbranched dextrins, preferentially hyperbranched and hydrogenated dextrins, can be applied before or after the use of these ingredients or active ingredients with an irritating effect in order to prevent, significantly reduce or even eliminate this irritating effect. In both cases, the hyperbranched dextrins, preferentially hyperbranched and hydrogenated dextrins, are present in cosmetic, dermocosmetic or topical formulations for dermatological, pharmaceutical, medical or veterinary use, which in fact do not contain ingredients or active ingredients with an irritating effect.

[0153] The presence of hyperbranched dextrins, preferentially hyperbranched and hydrogenated dextrins, in topical compositions for cosmetic, dermocosmetic, dermatological, pharmaceutical, medical, veterinary or household use, preferentially in topical compositions for cosmetic, dermocosmetic or dermatological use, which contain one or more ingredients or active ingredients with irritating effects, makes it possible to significantly reduce or even eliminate this irritating effect. This also makes it possible to increase the amount of products with irritating side effects compared to the amount of products normally used, in order to improve efficacy. This also makes it possible to administer products with irritating effects to sensitive skin.

[0154] Topical compositions for cosmetic, dermocosmetic, dermatological, pharmaceutical, medical, veterinary, or household use may contain one or more ingredients or actives that have a high potential to cause skin irritation, such as cosmetic or dermatological actives, surfactants, solvents, preservatives, fragrances, and detergents.

[0155] These ingredients or active ingredients having stimulating capabilities are as described above.

[0156] Dermatological composition or dermatologically acceptable composition The hyperbranched dextrins, preferentially hyperbranched and hydrogenated dextrins, may be incorporated into a dermatological composition or more generally into any composition made from a dermatologically acceptable medium and may preferentially come into contact with an epithelial tissue selected from keratinized multilayered squamous epithelium, non-keratinized multilayered squamous epithelium, stratified columnar epithelium, ciliated or non-ciliated pseudostratified columnar epithelium, preferentially come into contact with the epidermis, the oral cavity, the oral mucosa, the vaginal mucosa, the nasal passages, the nasal mucosa and most preferentially come into contact with the skin or the oral mucosa.

[0157] The present invention therefore also relates to a dermatological or dermatologically acceptable composition comprising hydrogenated and hyperbranched dextrin and a dermatologically acceptable medium.

[0158] The term "dermatologically acceptable composition" or "dermatologically acceptable" is understood to mean any composition that has no or few adverse side effects on the user who brings the dermatologically acceptable composition into contact with epithelial tissue, preferentially with the skin or mucous membranes of the user, in particular does not cause unacceptable reddening, burning, tightness or stinging, or more generally, irritation. Dermatologically acceptable compositions are therefore compatible with human epithelial tissue and human mucous membranes. Dermatologically acceptable compositions include pharmaceutical, medical and household compositions, including detergent compositions.

[0159] The composition according to the invention may also be another topical composition intended to prophylactically or therapeutically treat at least one epithelial tissue selected from keratinized multilayered squamous epithelium (epidermis), non-keratinized multilayered squamous epithelium (oral cavity, vaginal mucosa), stratified columnar epithelium (nares, conjunctival fornix), ciliated or non-ciliated pseudostratified columnar epithelium (nasal mucosa). As a result, this composition may be a topical composition for dermatological, pharmaceutical, medical or veterinary use for the care of skin and epithelial tissues.

[0160] Mode of Administration The dermatological compositions according to the invention may be in any pharmaceutical form normally used for topical application, such as aqueous, hydroalcoholic or oily solutions, lotion or serum type dispersions or solutions, milk type emulsions of liquid or semiliquid consistency obtained by dispersion of a fatty phase in an aqueous phase (O / W) or vice versa (W / O), or of soft, semisolid or solid consistency, cream type emulsions or suspensions, aqueous or anhydrous gels, anhydrous compositions, solid compositions of microemulsions, microcapsules, microparticles or ionic and / or non-ionic vesicular dispersions.

[0161] These compositions are prepared according to the usual methods known to those skilled in the art.

[0162] The composition may be applied before, during, or after the onset of at least one symptom selected from redness, heat, swelling, and pain, or inflammation of the skin or mucous membranes, and such application may be repeated or resumed as necessary.

[0163] This composition, when applied to the skin, may be more or less fluid and have the appearance of a cream, emulsion or microemulsion, ointment, milk, lotion, serum, paste, foam, mask, fluid, balm, oil, gel or salve. It may optionally be applied to the skin in aerosol form. It may also be provided in solid form and, for example, in stick or patch form, dry soap or cleansing bar.

[0164] It may be used as a skin care product, especially for leave-on application such as a day or night cream for the skin of the face and / or body, as a cleanser, as a make-up product, as a deodorant, as a shaving product, as an aftershave product, as an aftersun product, as a sun protection product or as a lip balm to protect the lips from the cold and / or sun and / or wind.

[0165] The composition according to the invention may also be a composition for scalp and hair care and may be in pharmaceutical form for rinse-off or non-rinse-off application.Examples of these forms are shampoos, hair conditioners, hair masks, serums, mousses, balms, creams, sprays, conditioners, detanglers, hair creams, and also in the form of treatment lotions, dye compositions, color shampoos, perm compositions, anti-hair loss lotions or gels, anti-parasitic shampoos, or conditioners.

[0166] The amount of hyper-branched dextrin in the composition can be varied to deliver an effective amount of hyper-branched dextrin to achieve the desired therapeutic response for a particular patient.

[0167] An "effective amount" or "therapeutically effective amount" of a compound is understood to mean a nontoxic but sufficient amount of the compound to provide the desired effect.

[0168] Typically, the amount or dose administered depends on various factors, such as the activity of the hyper-branched dextrin, the route of administration, the severity of the pathology, and the health condition and medical history of the patient being treated, body weight, diet, and possible combinations with other therapeutic agents. However, it is within the capabilities of a person skilled in the art to determine the appropriate dosage and to initiate treatment at a dosage lower than that required to obtain the desired therapeutic effect, and to gradually increase the dosage until the desired effect is obtained.

[0169] According to one embodiment, the content of hyper-branched dextrin ranges from 0.5 to 50% by weight, preferentially from 1 to 25% by weight, more preferentially from 1 to 15% by weight and even more preferentially from 2 to 10% by weight, based on the total weight of the cosmetic, dermatological or dermatologically acceptable composition.

[0170] Formulation ingredients According to one embodiment, the hyperbranched dextrin is administered topically.

[0171] The hyperbranched dextrin may be administered in several doses.

[0172] The dermatological composition or topical formulation according to the invention may also contain solvents selected according to the different ingredients and the mode of administration.

[0173] According to one embodiment, the composition according to the invention may comprise an aqueous phase comprising water and, optionally, one or more water-miscible organic solvents.

[0174] The term "water-soluble solvent" refers to a compound that is liquid at room temperature and miscible with water (greater than 50% by weight miscibility in water at 25° C. and atmospheric pressure).

[0175] The water-soluble solvents that may be used in the compositions according to the present invention may be volatile.

[0176] Among the water-soluble solvents that may be used in the composition according to the invention, mention may be made of monoalcohols having 1 to 5 carbon atoms, such as ethanol and isopropanol, C3-C4 ketones and C2-C4 aldehydes, and polyols, such as glycerol or glycerin, sorbitol or isosorbide.

[0177] The cosmetic composition may also include, in addition to hydrogenated and highly branched dextrins, the following: - One or more moisturizers: The humectants are selected from polyols and / or esters of fatty acids and polyethylene glycol.

[0178] "Polyol" is understood to mean any molecule that has in its structure at least two free hydroxy (-OH) groups. These polyols are preferably liquid at room temperature (25°C).

[0179] Typically, the polyol is selected from maltitol, mannitol, xylitol, erythritol, sorbitol, isosorbide, glycerol or glycerin, glucose, sucrose, polydextrose, hydrogenated glucose syrup, dextrin, maltodextrin, glucose syrup, and mixtures thereof.

[0180] Examples are Beaute by Roquette® PO 071 (INCI: Sorbitol), Beaute by Roquette® PO 260 (INCI: Mannitol), Beaute by Roquette® PO 370 (INCI: Xylitol), Beaute by Roquette® PO 455 (INCI: Hydrogenated Starch Hydrolysate), Beaute by Roquette® PO 500 (INCI: Isosorbide), Glycerin (INCI: Glycerin), Propylene Glycol (INCI: Propylene Glycol), Butylene Glycol (INCI: 1,3-BUTANEDIOL), all sold by ROQUETTE.

[0181] Among the esters of fatty acids and polyethylene glycol, mention may be made of the product sold under the name Glucamate SSE-20 by LUBRIZOL ADVANCED MATERIALS, Inc. (INCI: PEG-20 methyl glucose sesquistearate).

[0182] The composition comprises from 0.5% to 25% by weight of one or more humectants, preferably from 1% to 15% by weight, and even more preferably from 2% to 10% by weight of a polyol, relative to the total weight of the composition.

[0183] - One or more oils For the purposes of the present invention, "oil" is understood to mean a compound which is liquid at room temperature (25° C.) and which, when introduced into water at 25° C. in an amount of at least 1% by weight, is either completely insoluble in water or soluble to an extent of less than 10% by weight relative to the weight of the oil introduced into the water.

[0184] According to one embodiment, the oils are chosen from volatile oils, non-volatile oils and mixtures thereof. Preferably, these oils are vegetable or plant derived.

[0185] "Non-volatile oil" refers to an oil that remains on keratinous materials at room temperature and atmospheric pressure for at least several hours, and in particular for at least 10 -3 It is understood to mean an oil having a vapour pressure of less than mmHg (0.13 Pa).

[0186] Among the non-volatile oils, cetearyl isononoate, isotridecyl isononanoate, isostearyl isostearate, isopropyl isostearate, isopropyl myristate, isopropyl palmitate, butyl stearate, hexyl laurate, isononyl isononate, 2-ethylhexyl palmitate, 2-hexyldecyl laurate, 2-octyldecyl palmitate, 2-octyldodecyl myristate or lactate, 2-diethylhexyl succinate, diisostearyl malate, triacetin, tricaprin, caprylic / capric triglyceride, mixture of cococaprate and caprylate, C12-C15 alkyl benzoate, esters such as glyceryl triisostearate, butylene glycol cocoate; fatty esters such as glyceryl triisostearate, tocopherol acetate; higher fatty acids such as myristic acid, palmitic acid, stearic acid, behenic acid, oleic acid, linoleic acid, linolenic acid, or isostearic acid; higher aliphatic alcohols such as oleyl alcohol; vegetable oils such as avocado oil, camellia oil, hazelnut oil, camellia oil, cashew nut oil, argan oil, soybean oil, grape seed oil, sesame oil, corn oil, germ oil, rapeseed oil, sunflower oil, cottonseed oil, jojoba oil, peanut oil, macadamia oil, sweet almond oil, and olive oil; and mixtures thereof.

[0187] These non-volatile oils may also be of the hydrocarbon or silicone type, such as paraffin oil, squalene, petroleum jelly, dimethyl siloxane, and mixtures thereof.

[0188] According to one embodiment, the non-volatile oil is chosen from stearic acid, jojoba oil (INCI: Simmondsia Chinensis seed oil), grape seed oil (INCI: Vitis vinifera seed oil), macadamia oil (INCI: Macadamia ternifolia seed oil), refined oleic sunflower oil (Helianthus annuus seed oil), a mixture of caprate and coco-caprylate such as the product Miglyol Coco 810 (INCI: Coco-caprylate / caprate), sweet almond oil (INCI: Prunus Amygdalus Dulcis oil), sesame oil (INCI: Sesamum indicum seed oil).

[0189] Volatile oil is intended to mean an oil that is capable of evaporating from the skin within one hour at room temperature and atmospheric pressure. The volatile oil may be chosen, for example, from silicone oils or short-chain fatty acid triglycerides in order to reduce the greasy feel.

[0190] According to one embodiment, the oil is present in a content ranging from 0.5% to 70% by weight, preferably from 1% to 60% by weight, preferably from 2% to 50% by weight, preferably from 5% to 40% by weight, preferably from 5% to 30% by weight, relative to the total weight of the composition.

[0191] one or more waxes and / or one or more pasty compounds. "Wax" is intended to mean a lipid substance with a reversible liquid-solid state change and a melting point above 25°C, generally between 30°C and 90°C, which is liquid under the conditions of preparation of the composition and has an anisotropic crystalline structure in the solid state. The waxes used according to the invention may consist of polar or apolar waxes, or a mixture of the two. "Apolar" is understood to mean waxes that contain only carbon, hydrogen and / or phosphorus atoms, in particular hydrocarbons.

[0192] The polar waxes can be chosen from animal waxes, vegetable waxes, and synthetic or silicone waxes containing polar groups such as esters. Thus, mention may be made of carnauba wax, candelilla wax, beeswax (cera alba), Chinese insect wax (Ericerus pela), Japan wax, Japan wax, montan wax, triesters of C8-C20 acids and glycerin, such as glyceryl tribehenate, sold in particular under the trade name CETACENE by VEVY, acetylated glycol stearate, and mixtures thereof. These waxes can be used in particular in the form pre-dispersed in oil, as in the case of a mixture of candelilla wax and jojoba seed oil. Preferably, these waxes are vegetable or of vegetable origin.

[0193] According to one embodiment, the wax is present in a content ranging from 0.5 to 50% by weight, preferably from 1 to 25% by weight, and preferably from 5 to 10% by weight, relative to the total weight of the composition.

[0194] "Pasty compounds" is understood to mean lipophilic fatty substances which, like waxes, are capable of undergoing reversible liquid-solid state changes and which, in the solid state, have an anisotropic crystalline structure, but which differ from waxes in that they contain a liquid fraction and a solid fraction at a temperature of 23° C. These pasty compounds are preferably vegetable butters or butters of plant origin, such as shea butter or camellia butter.

[0195] According to one embodiment, the pasty compound is present in a content ranging from 0.5 to 50% by weight, preferably from 1 to 25% by weight, preferably from 5 to 10% by weight, relative to the total weight of the composition.

[0196] - one or more gelling agents Gelling agents are understood to mean compounds which, in the presence of a solvent, create more or less strong interpolymer bonds and thus induce a three-dimensional network that fixes the solvent. Gelling agents are also understood to mean thickening or rheological agents that act on the viscosity and flow properties of the aqueous or fatty phase.

[0197] The gelling agent makes it possible to increase the viscosity of the continuous phase, for example to adjust the viscosity of the continuous phase to a value in the range of 100 mPa.s to 20,000 mPa.s.

[0198] The gelling agent may be selected from polymers of synthetic or plant origin, preferentially of plant origin, chemically modified or not. It may therefore be selected from gums of plant origin, such as gum arabic, gum konjac, gum guar, or their derivatives; gums extracted from algae, such as alginates; gums of microbial fermentation origin, such as xanthan, for example the product Keltrol CG (INCI: Xanthan Gum) sold by the company CP KELCO or the product Xanthan Gum FNCS-PC (INCI: Xanthan Gum) sold by the company JUNGBUNZLAUER INTERNATIONAL AG, mannan, scleroglucan, or their derivatives; cellulose and its derivatives, such as carboxymethylcellulose or hydroxyethylcellulose; starches and its derivatives, such as modified starches, in particular pregelatinized, acetylated, hydroxypropylated, carboxymethylated, cationic, octenyl succinate, branched starches, optionally modified several times; synthetic polymers, such as polyacrylic acid or carbomer, and mixtures thereof.

[0199] Among the starches and starch-based blends, mention should be made of Beaute by Roquette® ST 118 (INCI: carboxymethyl starch), Beaute by Roquette® ST 720 (INCI: hydroxypropyl starch) and Beaute by Roquette® DS112 (INCI: starch acetate (and) hydroxyethylcellulose (and) xanthan gum), all sold by Roquette.

[0200] Among the carbomers, mention may be made, for example, of the products Carbopol Ultrez 30 (INCI: Carbomer) or CARBOPOL ETD 2050 POLYMER (INCI: Carbomer) manufactured by LUBRIZOL ADVANCED MATERIALS, Inc.

[0201] Mention may also be made of mixtures of gum arabic and xanthan gum, such as the product Solagum AX sold by the company SEPPIC (INCI: Acacia Senegal gum (and) xanthan gum), and mixtures of starch and cellulose derivatives, such as the product Beaute by ROQUETTE® DS112 sold by the company ROQUETTE (INCI: Starch acetate (and) hydroxyethylcellulose (and) xanthan gum).

[0202] The gelling agent may be a mineral gelling agent selected from magnesium silicate and / or aluminum silicate. An example of such a mineral gelling agent is Veegum® from Vanderbilt Minerals LLC, which is a magnesium aluminum silicate.

[0203] According to one embodiment, the gelling agent is present in a content ranging from 0.1 to 50% by weight, preferably from 0.5 to 25% by weight, preferably from 0.3 to 15% by weight, relative to the total weight of the composition.

[0204] - one or more binders The term "binder" refers to a compound that increases the cohesive strength of the cosmetic composition, which can be adjusted as a function of the amount and chemical affinity of the binder for the components of the cosmetic composition.

[0205] Typically, the binder is selected from caprylic / capric triglycerides, such as the products Labrafac CC (INCI: capric / caprylic triglycerides) or Cetyl Dimethicone (INCI).

[0206] The binder is present in the composition according to the invention in a content ranging from 0.5% to 20% by weight, preferably from 1 to 15% by weight, preferably from 5 to 12% by weight, relative to the total weight of the composition.

[0207] - one or more emulsifiers Cosmetic compositions according to the present invention may also comprise one or more oil-in-water (O / W) or water-in-oil (W / O) emulsifiers.

[0208] Oil-in-water (O / W) emulsifiers are emulsifiers having an HLB of 8 or greater and selected from sorbitan esters (which may be polyethoxylated), glycerol fatty acid esters, sucrose fatty acid esters or polyesters, polyethylene glycol fatty acid esters, polyether modified polysiloxanes, polyethylene glycol fatty alcohol ethers, alkyl polyglycosides and hydrogenated lecithins, fatty acids, sorbitan esters (this list is not limiting), and mixtures thereof.

[0209] Examples include Montanov 68 (INCI: Cetearyl Alcohol (and) Cetearyl Glucoside) sold by SEPPIC, Montanov L (INCI: C14-C22 Alcohols and C12-20 Alkyl Glucosides) sold by SEPPIC, Montanov 202 (INCI: Arachidyl Alcohol (and) Behenyl Alcohol (and) Arachidyl Glucoside) sold by CRODA, Citrol GMS 40 (INCI: Glyceryl Stearate) sold by CRODA, Imwitor 960K (INCI: Glyceryl Stearate) sold by BIESTERFELD, Imwitor 372P (INCI: Glyceryl Stearate Citrate) sold by BIESTERFELD, Glucate sold by LUBRIZOL ADVANCED MATERIALS, Inc. SS (INCI: Methyl glucose sesquistearate), several stearins (Polyglyceryl-6 distearate), Natragem E145 (INCI: Polyglyceryl-4 laurate / succinate (and) Aqua) sold by CRODA, Span 60 (INCI: Sorbitan stearate) sold by SIGMA ALDRICH.

[0210] Among the sorbitan esters, mention may be made, for example, of the product Span 20.

[0211] Among the fatty alcohols, mention may be made, for example, of the product sold under the name Promulgen D (INCI: Cetearyl Alcohol (and) Ceteareth-20).

[0212] The O / W emulsifier may advantageously be chosen from emulsifier systems composed of cyclodextrins and water-in-oil emulsifiers of natural origin, such as the emulsifier system marketed by Roquette Freres under the name Beaute by Roquette® DS 146, or from emulsifier systems based on modified starches and plant-based gums, such as Beaute by Roquette® DS 421, also sold by the Applicant.

[0213] Water-in-oil (W / O) emulsifiers are emulsifiers having an HLB of less than 8 and selected from non-ethoxylated polyol fatty acid esters, in particular from non-ethoxylated fatty acid esters of glycerol, polyglycerol, sorbitol, sorbitan, anhydrohexitols, such as, in particular, isosorbide, mannitol, xylitol, erythritol, maltitol, sucrose, glucose, polydextrose, hydrogenated glucose syrup, dextrins, and hydrolyzed starch.

[0214] The emulsifier is present in the composition according to the invention in a content ranging from 0.5% to 20% by weight, preferably from 1 to 15% by weight, preferably from 2 to 12% by weight, relative to the total weight of the composition.

[0215] One or more surfactants According to one embodiment, the composition according to the invention comprises at least one surfactant chosen from ionic, nonionic, anionic, cationic, or amphoteric or zwitterionic surfactants, these surfactants being chosen for their detergent and foaming function.

[0216] According to a further embodiment, the composition according to the invention comprises at least one surfactant selected from anionic surfactants, amphoteric surfactants, or zwitterionic surfactants.

[0217] The anionic surfactant is selected from carboxylate anionic surfactants, sulfate anionic surfactants, sulfonate surfactants, phosphate anionic surfactants, and mixtures thereof, preferably sulfonate anionic surfactants, carboxylate anionic surfactants, and mixtures thereof.

[0218] "Anionic surfactant" is intended to mean a surfactant that contains only anionic groups as ionic or ionizable groups. An entity is described herein as "anionic" if, under the conditions of use (e.g., medium, pH) of the compositions of the invention, it does not contain a cationic charge and has at least one permanent negative charge, or if it can be ionized to give a negatively charged entity. "Sulfate-based anionic surfactants" are surfactants that contain at least one sulfate functional group (-OSO3H or -OSO3H). - ), optionally containing a carboxylic acid or carboxylate functional group (-COOH or -COO - ), sulfonic acid functional group (-SO3H or -SO3 - ), and / or one or more other functional groups derived from an acid, such as a phosphoric acid functional group. By way of example, alkyl sulfates, alkyl ether sulfates, alkyl amido ether sulfates, alkyl aryl polyether sulfates, monoglyceride sulfates, and salts of these compounds are also sulfate anionic surfactants. The alkyl groups of these compounds mentioned by way of example contain 6 to 30 carbon atoms, and the aryl groups represent phenyl or benzyl groups. These compounds mentioned by way of example may be polyoxyalkylenated, in particular polyoxyethylenated, and contain 1 to 50 ethylene oxide units. "Non-sulfate anionic surfactants" is intended to mean surfactants that are not included in the definition of "sulfate anionic surfactants" as described above.

[0219] According to the present invention, it is also contemplated that: - Carboxylic acid anionic surfactants have at least one carboxylic acid or carboxylate functional group (-COOH or -COO -), but does not contain a sulfonic acid or sulfonate functional group (-SO3H or -SO3 - ) also has a sulfate functional group (-OSO3H or -OSO3 - ) is also not included. - Sulfonic acid anionic surfactants have at least one sulfonic acid or sulfonate functional group (-SO3H or -SO3 - ), optionally containing one or more carboxylic acid or carboxylate functional groups (-COOH or -COO - ), and / or phosphate, but may also contain sulfate functional groups (-OSO3H or -OSO3 - ) is not included. - Phosphate anionic surfactants have at least one phosphoric acid or phosphate functional group (-OPO3H2 or -OPO3 2- ), but does not contain a carboxylic acid or carboxylate functional group (-COOH or -COO - ) also has a sulfonic acid or sulfonate functional group (-SO3H or -SO3 - ) also has a sulfate functional group (-OSO3H or -OSO3 - ) is also not included.

[0220] In other words: - at least one sulfate functional group (-OSO3H or -OSO3 - ), and at least one carboxylic acid or carboxylate functional group (-COOH or -COO - ), for purposes of this invention and unless otherwise specified, are considered to be sulfate anionic surfactants. - at least one sulfate functional group (-OSO3H or -OSO3 - ), and at least one sulfonic acid or sulfonate functional group (-SO3H or -SO3 - ) are considered to be sulfate anionic surfactants within the meaning of the present invention and unless otherwise specified. - at least one sulfonic acid or sulfonate functional group (-SO3H or -SO3 -), and at least one carboxylic acid or carboxylate functional group (-COOH or -COO - Anionic surfactants containing at least one sulfate functional group (-OSO3H or -OSO3H) are considered to be non-sulfate sulfonate anionic surfactants within the meaning of the present invention and unless otherwise indicated. - ), and at least one sulfonic acid or sulfonate functional group (-SO3H or -SO3 - ), and at least one carboxylic acid or carboxylate functional group (-COOH or -COO - ) are considered to be sulfate anionic surfactants within the meaning of the present invention and unless otherwise specified.

[0221] The carboxylic acid anionic surfactants may be selected from the following compounds: acyl glycinates, acyl lactylates, acyl sarcosinates, acyl glutamates, alkyl-D-galactoside-uronic acids, alkyl ether carboxylic acids, alkyl(aryl) ether carboxylic acids, alkyl(amide) ether carboxylic acids, and salts of these compounds. The alkyl and / or acyl groups of these compounds contain from 6 to 30 carbon atoms, more preferably from 8 to 28, more preferably still from 10 to 24, and even better still from 12 to 22 carbon atoms. The aryl group preferably denotes a phenyl or benzyl group. These compounds may be polyoxyalkylenated, in particular polyoxyethylenated, and then preferably contain from 1 to 50 ethylene oxide units, and even better still from 2 to 10 ethylene oxide units. It is also possible to use C6-C24 alkyl monoesters and polyglycoside-polycarboxylic acids, such as C6-C24 alkyl polyglycoside citrates, C6-C24 alkyl polyglycoside tartrates, and salts thereof.

[0222] According to one embodiment, the carboxylate anionic surfactant is - C6 to C24, or even C12 to C20 acyl glutamates, such as stearoyl glutamate, and in particular sodium or disodium stearoyl glutamate, or cocoyl glutamate, and in particular sodium or disodium cocoyl glutamate; acyl sarcosinates, in particular C6 to C24, or even C12 to C20 acyl sarcosinates, such as cocoyl sarcosinates and in particular sodium cocoyl sarcosinate, lauroyl sarcosinates and in particular sodium lauroyl sarcosinate, palmitoyl sarcosinates and in particular sodium palmitoyl sarcosinate; - acyl lactylates, in particular C12 to C28, or even C14 to C24 acyl lactylates, such as behenoyl lactylates and in particular sodium behenolyl lactate, (iso)stearoyl lactylates and in particular sodium (iso)stearoyl lactylate; - acyl glycinates, in particular C6 to C24 or C12 to C20 acyl glycinates, such as cocoyl acyl glycinate, and in particular sodium cocoyl glycinate; - alkyl (C6-C30) ether carboxylic acids, in particular alkyl (C6-C24) ether carboxylic acids; - alkyl(C6-C30)aryl ether carboxylic acids, in particular alkyl(C6-C24)aryl ether carboxylic acids; - alkyl(C6-C30)amido ether carboxylic acids, in particular alkyl(C6-C24)amido ether carboxylic acids; and mixtures thereof, in particular in the form of an alkali or alkaline earth metal salt, ammonium or amino alcohol.

[0223] The anionic surfactants may be selected from the following compounds: alkylsulfonates, alkylamidosulfonates, alkylarylsulfonates, C6-C24 alkyl polyglycoside sulfosuccinates, alpha-olefinsulfonates, kerosene sulfonates, alkylsulfosuccinates, alkylethersulfosuccinates, alkylamidosulfosuccinates, alkylsulfoacetates, N-acyltaurates, acylisethionates; alkylsulfolaurates; and salts of these compounds, the alkyl groups of which contain from 6 to 30 carbon atoms, in particular from 12 to 28, better still from 14 to 24 or even from 16 to 22 carbon atoms, the aryl groups preferably designating phenyl or benzyl groups, and these compounds may be polyoxyalkylenated, in particular polyoxyethylenated, in such a case preferably comprising from 1 to 50 ethylene oxide units, better still from 2 to 10 ethylene oxide units.

[0224] According to one embodiment, the anionic surfactant is selected from C6-C24, particularly C12-C20 alkyl sulfosuccinates, in particular lauryl succinate; C6-C24, particularly C12-C20 alkyl ether sulfosuccinates; (C6-C24) acyl isethionates, preferably (C12-C18) acyl isethionates; alpha-olefin sulfonates; and mixtures thereof, particularly in the form of an alkali or alkaline earth metal, ammonium, or amino alcohol salt.

[0225] According to one embodiment, the anionic surfactant may be selected from C6-C24 alkyl monoesters and polyglycoside-dicarboxylic acids, such as alkylglucoside citrates, alkylpolyglycoside tartrates and alkylpolyglycoside sulfosuccinates, alkylsulfosuccinamates, acyl isethionates, and N-acyltaurates, the alkyl or acyl groups of all these compounds preferably containing 12 to 20 carbon atoms.Another group of anionic surfactants that may be used in the compositions of the present invention is that of acyl lactylates, the acyl groups of which contain 8 to 20 carbon atoms. Further examples include alkyl-D-galactosiduronic acids and their salts, and also polyoxyalkylenated (C6-C24) alkyl ether carboxylic acids, polyoxyalkylenated (C6-C24) alkyl (C6-C24) aryl ether carboxylic acids, polyoxyalkylenated (C6-C24) alkyl amido ether carboxylic acids, and their salts, particularly those having 2 to 50 ethylene oxide units, and mixtures thereof.

[0226] The phosphate anionic surfactant is selected from C6-C24 alkyl phosphates, particularly C12-C20 alkyl phosphates; C6-C24 alkyl ether phosphates, particularly C12-C20 alkyl ether phosphates; and mixtures thereof.

[0227] The amphoteric or zwitterionic surfactants may be selected from secondary or tertiary or quaternary aliphatic amine derivatives, the aliphatic group being linear or branched, containing 8 to 22 carbon atoms and containing at least one anionic group, such as a carboxylate, sulfonate, sulfate, phosphate or phosphonate group. Mention may also be made of (C8-C20) alkyl betaines, such as coco betaine, sulfo betaine, (C8-C20) alkyl sulfo betaine, (C8-C20) alkyl amido alkyl (C3-C8) betaine, such as cocamidopropyl betaine; or (C8-C20) alkyl amido alkyl (C6-C8) sulfo betaine.

[0228] The cationic surfactant may be chosen from cetrimonium chloride, commercially available under the reference Microcare Quat CTC 30.

[0229] The surfactant is present in the composition according to the invention in a content ranging from 0.1% to 40% by weight, preferably from 0.5 to 30% by weight, preferably from 1 to 20% by weight, preferably from 2 to 12% by weight, relative to the total weight of the composition.

[0230] - one or more film-forming agents The film former may be selected from naturally occurring polymers such as hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), or synthetic polymers such as polyvinyl alcohol (PVA), and / or plasticizers other than polyols such as polyethylene glycol, triethyl citrate, polysorbate, or waxes such as carnauba wax or hydrogenated castor oil.

[0231] Another film former of vegetable origin is Beaute by Roquette® ST 720 hydroxypropylated pea starch sold by ROQUETTE.

[0232] The film-forming agent is present in the composition according to the invention in a content ranging from 0.1% to 20% by weight, preferably from 0.5 to 15% by weight, preferably from 1 to 12% by weight, relative to the total weight of the composition.

[0233] - One or more dyes The cosmetic composition according to the invention may further comprise at least one dye selected from water-soluble or liposoluble dyes, fillers having the effect of coloring and / or opacifying the composition and / or coloring keratinous substances, preferentially the skin or the hair, such as pigments, nacres, lakes (water-soluble dyes adsorbed on inert mineral carriers), and mixtures thereof. These dyes may be optionally surface-treated with hydrophobic agents such as silanes, silicones, fatty acid soaps, C9-15 fluoroalcohol phosphates, acrylate / dimethicone copolymers, C9-15 fluoroalcohol phosphate / silicon mixed copolymers, lecithin, carnauba wax, polyethylene, chitosan, and optionally amino acids that may be acylated, such as lauroyl lysine, disodium stearoyl glutamate, and aluminum acyl glutamate, phytic acid. Another natural colorant is the caramel colorant Beaute by Roquette® CC 001 sold by ROQUETTE.

[0234] "Pigment" means a white or colored mineral or organic particle intended to color and / or opacify a cosmetic composition.

[0235] Among the pigments, mention may be made of mineral or organic, natural or synthetic pigments. Examples of pigments include, in particular, oxides of iron, titanium or zinc, but also composite pigments and goniochromatic, pearlescent, interference, photochromic or thermochromic pigments, this list being non-limiting.

[0236] Among the pigments surface-treated with lecithin are UNIPURE WHITE LC981 HLC (INCI: CI 77891 (and) Hydrogenated Lecithin, UNIPURE YELLOW LC182 HLC (INCI: CI 77492 (and) Hydrogenated Lecithin), UNIPURE BLACK LC989 HLC (INCI: CI 77499 (and) Hydrogenated Lecithin, UNIPURE RED LC381 (INCI: CI 77491 (and) Hydrogenated Lecithin) from Sensient Cosmetic Technologies.

[0237] Among the pigments surface-treated with phytic acid are Unipure White LC 985 PHY (INCI: CI 77891 (and) phytic acid (and) sodium hydroxide), Unipure Yellow LC 188 PHY (INCI: CI 77492 (and) phytic acid (and) sodium hydroxide), Unipure Red LC 388 PHY (INCI: CI 77491 (and) phytic acid (and) sodium hydroxide), and Unipure Black LC 998 PHY (INCI: CI 77499 (and) phytic acid (and) sodium hydroxide) from Sensient Cosmetic Technologies.

[0238] "Pearling" is intended to mean any iridescent or non-iridescent colored particle that has a color effect due to optical interference.

[0239] Among the pearlescent agents there may be mentioned titanium mica covered with metal oxides such as iron oxide or titanium oxide.

[0240] According to one embodiment, the makeup and / or skin care composition according to the invention comprises at least colored particles, preferentially pigments such as iron oxide pigments and / or pearlescent agents.

[0241] The dyes are present in the composition according to the invention in a content ranging from 0.05% to 20% by weight, preferably from 1 to 15% by weight, and preferably from 0.5 to 12% by weight, relative to the total weight of the composition.

[0242] One or more fillers or sensory powders This term is intended to mean any shape (especially spherical or lamellar), inorganic or organic particles, which are insoluble in the composition. Examples of fillers or sensuous powders are talc, boron nitride, starch, such as Beaute by Roquette® ST 005 and Beaute by Roquette® ST 012 sold by ROQUETTE, polyamides, silicone resins, silicone elastomer powders, and acrylic polymer powders, specifically powders of poly(methyl methacrylate) or powders of styrene acrylate copolymers (Sunsphere Powders from Dow).

[0243] The fillers are present in the composition according to the invention in a content ranging from 0.5% to 20% by weight, preferably from 1 to 15% by weight, preferably from 3 to 12% by weight, relative to the total weight of the composition.

[0244] One or more sensory agents Sensate agents can be used to modify the sensory profile of cosmetic or dermatological compositions to make them more pleasant to use on the skin. Sensate agents can be selected from modified starches such as carboxymethylated starches, for example Roquette's Beaute by Roquette® ST 118, silicas, or talc, or mixtures thereof. These sensate agents provide a soft feel for solid compositions or a cushioning effect for compositions in liquid or gel form.

[0245] The sensate is present in the composition according to the invention in a content ranging from 0.1% to 20% by weight, preferably from 1 to 15% by weight, preferably from 3 to 12% by weight, relative to the total weight of the composition.

[0246] - one or more active ingredients In addition to the hyper-branched dextrin, the cosmetic composition may contain one or more active ingredients.

[0247] The applicant has discovered that hyperbranched dextrins, preferentially hyperbranched and hydrogenated dextrins, are fairly inert, have low reactivity and good compatibility with most active ingredients used in dermatological compositions / topical formulations, these active ingredients may be of a wide range of chemical types, these active ingredients may be selected from moisturizing agents, emollients, film formers, barrier agents, anti-staining agents, firming agents, anti-aging agents, antioxidants, exfoliants, collagen stimulators, anti-acne agents, sebum reducing agents, blood circulation stimulators, cooling agents, antibacterial agents, antifungal agents, anti-inflammatory agents, soothing agents, anti-irritating agents, healing agents, slimming agents, pigments, colorants, mattifying agents and fragrances.

[0248] Among the analgesics, those extracted from plants are used with preference: C-glycosides, such as those described in French Patent No. 2 902 998, are particularly suitable as sedatives.

[0249] Preferentially, the hyper-branched dextrin may be combined with another anti-inflammatory cosmetic active ingredient or with a soothing active ingredient.

[0250] Active ingredients include those set forth in the table below.

[0251] [Table 1]

[0252] The active ingredient is present in the composition according to the invention in a content ranging from 0.05% to 20% by weight, preferably from 0.1 to 10% by weight, preferably from 0.5 to 6% by weight, relative to the total weight of the composition.

[0253] The dermatological composition according to the invention is particularly suitable for intolerant and / or sensitive skin, as well as for sensitive scalps.

[0254] Sensitive or intolerant skin is defined in French Patent No. 2 918 886.

[0255] Intolerant skin is skin that reacts to various factors, such as the application of cosmetic or dermatological products, with a sensation of heat, tightness, stinging, and / or redness. Generally, these symptoms are associated with erythema and hyperseborrheic or acneic skin, or even rosacea, with or without dry patches.

[0256] Sensitive skin is skin that reacts with pruritus, in other words itching or burning, to various factors such as the environment, emotions, foods, wind, rubbing, razors, hard water with a high lime content, temperature changes, or wool, etc. In most cases, skin sensitivity translates into visible signs such as skin redness, a feeling of hot skin or scalp, or even a feeling of pain.

[0257] "Sensitive scalp" is understood to mean a scalp in which itching and / or tingling and / or heat sensations are essentially caused by local factors such as rubbing, soaps, detergents, hard water with high lime content, shampoos, or lotions. These sensations can also be caused by factors such as the environment, emotions, and / or food. Scalp erythema, hyperseborrhea, and dandruff are often associated with the above symptoms. EXAMPLES

[0258] Example 1: In vitro determination of the effect of hyperbranched and hydrogenated dextrins on skin inflammation in a 2D reconstructed human epidermis model The aim of this study was to determine the effect of hyperbranched and hydrogenated dextrins on biomarkers of inflammation using a two-dimensional (2D) human epidermal reconstruction model after inflammatory pretreatment. In this example, the hyperbranched and hydrogenated dextrin Nutriose® HM 06 sold by the applicant was used.

[0259] Materials and Methods Reconstructed human epidermis model In vitro reconstructed human skin equivalents closely mimic normal human skin. These models largely reproduce the barrier function properties of normal human skin, so they can be used to screen potential skin irritants. The model used is a two-dimensional reconstruction of human epidermis adapted from the method by Poumay et al., 2004 (Poumay, Y., Dupont, F., Marcoux, S., Leclerk-Smekens, M., Herin, M. And Coquette, A. (2004) A simple reconstructed human epidermis: preparation of the culture model and utilization in vitro studies. Arch. Dermatol. Res. 296: 203-211). This model contains a monolayer of normal human epidermal keratinocytes (NHEK, one of the main cell types of the skin) cultured on an inert polycarbonate insert.

[0260] Test substances can be applied topically directly to the epidermal surface and their irritant potential and / or efficacy can be assessed using several parameters, including the expression levels of key cellular markers of inflammation.

[0261] Tissue exposure to sample The epidermis was treated with a 0.5% aqueous solution of sodium lauryl sulfate (SLS) for 6 hours to induce inflammation of the reconstructed epidermis, and then the surface of the epidermis was rinsed with 500 μL of PBS. 20 μL of different concentrations of hydrogenated and highly branched dextrin (10 and 5% in ultrapure water) and 0.05% betamethasone cream (Biogaran cream, a corticoid with anti-inflammatory function) were topically applied to the epidermis for 20 hours at 37° C. Within 20 hours of rinsing with PBS, no SLS was applied to the control.

[0262] Under the same conditions, a negative control (UTC) was subjected to the various technological steps without application of SLS or samples. Sodium lauryl sulfate (SLS, 0.5% in water) is used as a positive control for epidermal inflammation.

[0263] MTT cell proliferation assay Irritating chemical compounds are able to penetrate the stratum corneum and are cytotoxic to cells in the underlying layers. Cell survival has been shown to directly correlate with the irritating ability of chemical compounds. Cell survival is measured upon metabolism of the vital dye MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-bromide diphenyl tetrazolium, thiazolyl blue; EINECS number 206-069-5, CAS number 298-93-1)] by mitochondrial succinate dehydrogenase to a blue formazan salt, which is quantitatively measured after extraction from the tissue.

[0264] The colored solution is measured spectrophotometrically at 570 nm using a Molecular Devices Vmax microplate reader and absorbance values ​​are recorded using SOFTmax PRO v4.7.1 software. Statistical analysis is performed using GraphPad Prism v5.03 software.

[0265] According to the results of this study, - If survival is less than 50%, the ingredient is an irritant - If survival is greater than 50%, the component - It is a mild irritant if it activates biomarkers of inflammation. - If it does not activate biomarkers of inflammation, it is a non-irritant.

[0266] Inflammatory marker assays Interleukins IL-1α and IL-8, as well as tumor necrosis factor-α (TNF-α) are measured to determine whether the treatment induced an inflammatory response in the treated tissue.

[0267] For this, cell supernatants are collected after the required treatment time and the presence of inflammatory markers is quantitatively determined using commercially available ELISA kits.

[0268] [Table 2]

[0269] These ELISA kits are designed specifically for the quantitative measurement of the aforementioned markers in culture supernatants using specific human antibodies. Samples and a range of standards are placed in duplicate in each well (96-well plate). Targeted markers present in the samples are bound by the antibodies immobilized at the bottom of the wells. The wells are washed and biotinylated antibodies are added. After washing, HRP-streptavidin is placed in the wells. These are washed again and a solution of TMB substrate is added to the wells, which develops a color proportional to the amount of bound marker. The developer changes the color from blue to yellow and the intensity is measured at 450 nm using a Molecular Devices Vmax microplate reader. The absorbance values ​​are recorded and analyzed using SOFTmax PRO v4.7.1 software. The inflammatory response is interpreted as a ratio of sample vs. untreated ≧2.

[0270] Semi-quantitative fluorescent assay for cytokines To obtain a more complete profile of the anti-inflammatory effects induced by hydrogenated and highly branched dextrins, a panel of cytokines was assayed on slides by a semi-quantitative assay: cell culture supernatants collected after epidermal treatment are tested using the Human Cytokine Array G3 kit (RayBiotech).

[0271] The supernatant is placed at a ratio of 100 μL per well on glass slides containing different specific antibodies. A cocktail of biotin-conjugated secondary antibodies is then added. Upon addition of streptavidin, the signal intensity is detected by fluorescence. Each step is followed by several washes.

[0272] result MTT cell proliferation assay The cytotoxicity of the samples was tested using an epidermal model and is expressed as a percentage of untreated control (UTC) tissue.

[0273] [Table 3] * Average of three replicates; ** SD: standard deviation

[0274] There was a significant difference in cell survival between untreated controls and treated areas, demonstrating the effect of inflammatory treatment with SLS.

[0275] After 20 hours, cell survival in the presence of 0.5% SLS and Nutriose HM 06 hyperbranched dextrin is greater than 50%, therefore Nutriose HM 06 hyperbranched dextrin is not an acute irritant to the epidermis. As expected, the same was true for samples treated with 0.5% SLS and 0.05% betamethasone. Cell survival measured in the presence of 0.5% SLS and Nutriose® HM 06 hyperbranched dextrin was as good as in the presence of 0.5% SLS and betamethasone. Since this cell survival test established that Nutriose HM 06 hyperbranched dextrin is not an acute irritant, a test on the expression of inflammatory markers could be carried out to determine whether this dextrin could qualify as either a mild irritant in the absence of a reduction in inflammatory marker expression, or an anti-irritant in the presence of a reduction in the expression of at least one major inflammatory marker.

[0276] Testing for inflammatory markers IL-1α, IL-8, and TNF-α

[0277] [Table 4]

[0278] Inflammatory marker concentrations were averaged from two replicates of epidermis, n=3 in the ELISA test (except for IL-8, n=2). The ratio (marker concentration in the presence of sample / marker concentration in untreated control) was calculated for each formulation tested.

[0279] A ratio of 2 or greater reflects overexpression of the inflammatory marker, while a ratio of less than 2 indicates non-expression of the inflammatory marker.

[0280] The hyperbranched dextrin according to the invention "Nutriose® HM 06" significantly reduces IL-1α expression (25 and 28%). Betamethasone also significantly reduces IL-1α expression (33%). Thus, no significant differences were observed between the compounds according to the invention and the positive control betamethasone, proving the anti-inflammatory effect of the compounds according to the invention.

[0281] Neither hydrogenated nor highly branched dextrin at any concentration reduced interleukin IL-8 expression after epidermal inflammation, and betamethasone cream also had no effect on the IL-8 ratio.TNF-α expression was not high enough to be detected according to the ELISA kit calibration curve.

[0282] Testing for four inflammatory markers: IL-1α, IL-1β, RANTES, and VEGF.

[0283] According to the results obtained by an ELISA test for the inflammatory marker IL1-α, the effect of a 5% concentration of hyperbranched dextrin "Nutriose® HM 06" was evaluated after inflammation of the reconstructed epidermis with 5% SLS.

[0284] [Table 5]

[0285] The ratio (fluorescent signal intensity of the marker in the presence of sample / fluorescent signal intensity of the marker in the untreated control) was calculated for each treatment from n=3 epidermal culture supernatants (except for the untreated control, n=2).

[0286] A ratio above 1.5 reflects overexpression of inflammatory markers.

[0287] A ratio below 0.65 indicates underexpression of the inflammatory marker.

[0288] According to the supplier's criteria, a signal is usable if it is greater than the mean +2 SD of the background noise. Over- or under-expression of five markers was observed with 0.5% SLS inflammation. A decrease in the expression of these markers was also observed with the addition of "Nutriose® HM 06" hyperbranched dextrin-based treatment.

[0289] Thus, "Nutriose® HM 06" hyperbranched dextrin: - Reduces IL-1α expression (relative to SLS alone) below the critical limit of 1.5 - Reduce IL-1β expression to less than 0.65 (vs. SLS alone) - reduce the expression of IL-15 to less than 0.65 (compared to untreated controls) - Reduce VEGF expression (compared to SLS alone), bringing it closer to the critical threshold of 1.5 - Reduces RANTES expression (vs. SLS alone).

[0290] Thus, Nutriose HM 06 hyperbranched dextrin reduces the expression of key markers of inflammation (IL-1 alpha and IL-1 beta) and can therefore be described as an anti-irritant. The dextrin has anti-inflammatory properties.

[0291] Example 2: In vitro determination of the effect of hyperbranched dextrins on membrane integrity in a 3D reconstructed human epidermis model The aim of this study was to assess the membrane integrity of skin cells in a three-dimensional (3D) reconstructed human epidermis model by measuring the amount of the enzyme lactate dehydrogenase (LDH) in the culture supernatant using a colorimetric assay. LDH is an enzyme released in the event of cell death. The absence of LDH secretion is an indication that the integrity of the epidermal cell membrane is preserved.

[0292] protocol Samples of 3D reconstructed human epidermis were immersed in an aqueous solution containing 0.5% by weight sodium lauryl sulfate for 6 hours. The solution was then removed and the samples were immersed for 20 hours in different solutions: one sample in a 5% by weight aqueous solution of Nutriose® HM 06, another sample in a 0.5% by weight aqueous solution of bisabolol, and another sample in a 0.5% by weight aqueous solution of betamethasone. The amount of LDH secreted in the supernatant was then determined colorimetrically.

[0293] result

[0294] [Table 6]

[0295] Roquette's Nutriose® HM 06 hyperbranched dextrin maintains the integrity of reconstituted human epidermal cell membranes as effectively as betamethasone.

[0296] Example 2: Clinical study of shaving-induced transepidermal water loss The objective of the study was to determine in a clinical study on volunteers the effect of a hyperbranched dextrin sold under the reference Nutriose® HM 06 by Roquette on the transepidermal water loss (or TEWL) induced by shaving the facial skin by topical application of said dextrin in the form of a lotion (aftershave).

[0297] Volunteers and Products This non-invasive, single-center study was conducted on 60 male volunteers aged 30-55 years who had sensitive skin (based on self-report), used a mechanical razor daily, and applied aftershave. Volunteer inclusion criteria are shown in the Table.

[0298] [Table 7]

[0299] Volunteers were divided into three uniform groups of 20 volunteers, with each group receiving a set of twin-blade razors, a "commercial reference" shaving cream, and an aftershave lotion according to the table below.

[0300] Aftershave Cream Composition

[0301] [Table 8]

[0302] device The faces of the volunteers are evaluated by measuring the transepidermal water loss (TEWL). This measurement allows the barrier function of the skin to be evaluated, the value of the water loss being inversely proportional to the barrier function of the skin. The transepidermal water evaporation (expressed in g / h / m2) is measured with a Tewameter TM300® from Courage & Khazaka electronics, using the open room diffusion technique. Approximately 20 consecutive measurements are made on the surface of the face that has been shaved, and the average value is used.

[0303] Study Procedure Volunteers replaced their regular razor and shaving cream with the study razor and shaving cream 3 days prior to the start of the study. The study then began by assessing the volunteers' faces in the lab after shaving and applying aftershave lotion in the lab (the "Day 0" measurement). The measurement was repeated 10 minutes after the "Day 0" measurement.

[0304] On days 0-13, volunteers shaved at home daily using a new razor for each shave, as well as the study shaving cream and aftershave. On day 14, volunteers returned to the lab for a facial assessment following the same protocol as on day 0, i.e., a post-shave assessment, after which they applied aftershave in the lab, followed by a second measurement 10 minutes after the first measurement.

[0305] On days 14-27, volunteers repeated the same protocol as on days 0-13. Then on day 28, they returned to the lab for a final facial evaluation using the same protocol as on days 0 and 14, i.e., after shaving and application of aftershave lotion on day 28, followed by a second measurement 10 minutes after the first measurement.

[0306] result

[0307] [Table 9]

[0308] [Table 10]

[0309] Thus, this study showed that application of an aftershave lotion containing Nutriose HMC 6, a highly branched and hydrogenated dextrin according to the present invention, reduced intracellular water loss on days 14 and 28 compared to a placebo lotion from day 0. It also reduced water loss to the same extent as the reference product on day 14 and to a greater extent than the reference product on day 28.

[0310] Example 3: Clinical Study of Transepidermal Water Loss (TEWL) and Redness Induced by Sodium Lauryl Sulfate The aim of the study was to determine the effect of a hyperbranched dextrin sold by Roquette under the reference Nutriose® HM 06 on redness caused by skin irritation on the inner forearm during clinical trials on volunteers, by patch test with 10% SLS.

[0311] Volunteers and Products The volunteers were the same as in the clinical study of Example 2 (shaving study) and were divided into the same groups using the same products (Table 6 in Example 2).

[0312] material Skin color was assessed colorimetrically using a Minolta CM2600D™ spectrophotometer. Color measurements were performed using the following parameters: standard 10° viewing angle, D65 illumination corresponding to daylight, measurement on an 8 mm2 area, L * a * b * Uses color space and SCI methods to avoid surface conditions (including specular reflection).

[0313] Vertical dimension L * represents the luminance (or brightness) with values ​​ranging from 0 (black) to 100 (white). * determines the range from 600 levels on the red axis (positive values ​​of +299) through gray (value 0) to green (negative values ​​of -300). *determines the range from the 600 level (positive value of +299) on the yellow axis through gray (value 0) to blue (negative value of -300). For this study, the parameter a, which represents skin redness, * It was decided.

[0314] Study Protocol At the beginning of the study (day 0), skin color and TEWL measurements were taken on the defined areas on both forearms of the volunteers. Then, 10% SLS patches were placed on the two defined areas on the forearms of each volunteer. The volunteers kept the patches on for 20 hours, and removed the patches 4 hours before the measurements on day 1, so that color and TEWL measurements were taken on both forearms of all volunteers on day 1. Immediately after the measurements on day 1, aftershave lotion was applied to the SLS patch-treated area on the right forearm, and then color and TEWL were measured 5, 10 and 30 minutes after this application. The left forearm was not treated.

[0315] Volunteers applied aftershave lotion nightly to the SLS-treated area of ​​the right forearm on days 1-6. The left forearm received no treatment. Color and TEWL were measured on days 2, 3, 4, and 7 in the aftershave-treated and control areas.

[0316] result

[0317] [Table 11]

[0318] To compare the change in redness between different groups, the variation in redness between the different measurement times was calculated for example for treated areas of the skin:

[0319] [Formula 1] For all three groups, Δtreatment((day x)-day 1)=(a of the treatment area on day x) * )-(a in the treatment area on day 1 * ).

[0320] [Table 12]

[0321] The table shows the variation in redness over time between treated and untreated areas of skin.

[0322] Nutriose® HM 06 hyperbranched dextrin significantly reduced SLS-induced redness as early as 10 minutes compared to the placebo and reference groups, and this reduction was maintained for up to 7 days. The reduction in skin redness by application of Nutriose HM 06 hyperbranched dextrin indicated that this dextrin reduced skin inflammation caused by the 10% SLS patch.

[0323] Moreover, this reduction in inflammation was faster than the reference group and therefore faster than the well-known anti-inflammatory bisabolol.

[0324] [Table 13]

[0325] The table shows the transepidermal water loss in the treated areas of the forearm.

[0326] [Table 14]

[0327] Table 14 shows the change in transepidermal water loss in the treated areas of the forearm compared to day 1.

[0328] Nutriose® HM 06 hyperbranched dextrin significantly reduced transepidermal water loss as early as 30 minutes after application, and then gradually increased over the 2-7 day treatment period to reach a water loss reduction value of about 6.6 units greater than that of the placebo group (i.e., a difference of about 195%). Thus, the hyperbranched dextrin helped maintain skin hydration by maintaining the skin barrier function.

[0329] Example 4: Cosmetic formulations containing hydrogenated and highly branched dextrins as claimed herein "Skin Lover" Cream (SC-079-005)

[0330] [Table 15]

[0331] Preparation protocol: At 45°C, Nutriose® HM 06 was added to water and mixed with a deflocculator at 500 rpm until a clear solution was obtained. The ingredients of phase A2 were then mixed together in water with stirring at 500-1000 rpm. Phase A3 was then added to phase A1+A2 and stirred at 1500 rpm for 10 minutes. Separately, phase B was prepared by heating to 45°C, then liquid phase B was emulsified in phase A1+A2+A3 at 45°C with stirring at 2000-3000 rpm for 15 minutes. It was then cooled to room temperature and phases C and D were added. It was finished by adding E and F, previously dissolved in a small amount of water. The result was a blue emulsion with a Brookfield viscosity of 4500-5500 mPa.s (SP3 movement, 20 rpm, 20°C).

[0332] After-sun cream

[0333] [Table 16]

[0334] Preparation protocol: Phase A and Phase B were prepared in two separate beakers at 70°C. Phase B was then emulsified in Phase A under high shear mixing for 10 minutes. This was followed by cooling to 20°C + / - 2°C. Phase C was then added under stirring, followed by Phase D. Finally, the pH was adjusted to 6. A white cream was obtained with a Brookfield viscosity of 3500 mPa.s + / - 700 (spindle number 4, 20 rpm).

[0335] Aftershave Gel

[0336] [Table 17]

[0337] Preparation Protocol: Isosorbide and Nutriose HMC 06 was premixed with the required amount of water for phase A, then Beaute by Roquette DS 112 starch was dispersed therein for 30-40 minutes at 80° C. Phases B1 and B2 were then added successively and the pH was adjusted to 6. A translucent cream was obtained with a Brookfield viscosity of 3500 mPa.s+ / -700 (spindle number 4 at 20 rpm).

[0338] Soothing oil-in-water emulsion

[0339] [Table 18]

[0340] Preparation protocol: Nutriose HMC 06 was added to half the volume of water required for the formulation at 45°C and stirred with a deflocculator at 500 rpm until a clear solution was obtained. Separately, the ingredients of phase A2 were mixed in half the volume of water required for the formulation with stirring at 500-1000 rpm. Phase A1 was then mixed with phase A2 and phase A3 was added with stirring at 1500 rpm for 10 minutes. Separately, phase B was prepared by heating to 45°C. Phase B was then emulsified in phase A1+A2+A3 with vigorous stirring at 2000-3000 rpm for 15 minutes at 45°C. It was cooled to 20°C+ / -2°C and then phases C, D, E and F were added successively with stirring at 500 rpm and the pH was adjusted to 5.3+ / -0.2. The result was a blue emulsion with a Brookfield viscosity of 4500-5500 mPa.s (spindle number 3 at 20 rpm).

[0341] Soothing and Repairing Hand Cream

[0342] [Table 19]

[0343] Preparation protocol: Nutriose HMC 06 was added to the volume of water required for the formulation at 45°C, stirred with a deflocculator at 500 rpm until a clear solution was obtained, then cooled to 20°C ± 2°C. Beaute by Roquette DS 421 was then dispersed in phase A while stirring with a deflocculator at 1000 rpm for about 10 minutes in order to hydrate this ingredient, which was observed visually by its opalescence. Phase C was prepared separately. At room temperature (20°C + / - 2°C), phase C was slowly added to phase A + B while stirring with a deflocculator at 2000-3000 rpm, then stirring was maintained for 10 minutes. Finally, phase D was added while stirring at 1000-2000 rpm, then adjusted to pH 4.5-4.7. A yellow cream was obtained with a Brookfield viscosity of 8800 mPa.s (spindle 3 at 20 rpm).

[0344] Soothing cleansing cream (TQ-027-001)

[0345] [Table 20]

[0346] Soothing Hair Conditioning Gel (HC-040-001)

[0347] [Table 21]

[0348] Soothing Hair Conditioning Cream (HC-040-002)

[0349] [Table 22]

Claims

1. 1. A hyperbranched dextrin for topical use in the prevention or treatment of at least one symptom selected from redness, heat, swelling, and pain, said hyperbranched dextrin having, relative to the total of 1,2, 1,3, 1,4, and 1,6 bonds: - up to 90% 1,4 glucosidic bonds, Hyperbranched dextrins, characterized in that they contain at least 5% 1,6 glucosidic bonds.

2. Hyperbranched dextrin, - at least 5%, preferentially at least 10%, more preferentially at least 12% and most preferentially at least 15% 1,6 glucosidic bonds relative to said total of 1,2, 1,3, 1,4 and 1,6 bonds; at most 70%, preferentially at most 60% and most preferentially at most 50% of 1,4 glucosidic bonds relative to said total of 1,2, 1,3, 1,4 and 1,6 bonds, - at least 1%, preferentially at least 5%, more preferentially at least 10% and most preferentially at least 20% of 1,3 glucosidic bonds relative to said total of 1,2, 1,3, 1,4 and 1,6 bonds; - at least 1%, preferentially at least 5%, more preferentially at least 10% and most preferentially at least 20% of 1,2 glucosidic bonds relative to said sum of 1,2, 1,3, 1,4 and 1,6.

3. The hyperbranched dextrin is - 42 to 50% 1,4 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; - from 5% to 40% of 1,6 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; - from 1 to 20% of 1,3 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; - 1 to 20% of 1,2 bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds 2. A hyperbranched dextrin for use according to claim 1, characterized in that it has:

4. 2. The hyperbranched dextrin for use according to claim 1, characterized in that the dextrin is a hyperbranched hydrogenated dextrin.

5. 2. The hyperbranched dextrin for use according to claim 1, characterized in that the pathology is located in at least one epithelial tissue selected from keratinized multilayered squamous epithelium, non-keratinized multilayered squamous epithelium, stratified columnar epithelium, ciliated or non-ciliated pseudostratified columnar epithelium.

6. 2. The hyperbranched dextrin according to claim 1 for the prevention or treatment of skin inflammatory conditions.

7. 2. The hyperbranched dextrin according to claim 1 for the prevention or treatment of symptoms of mucosal inflammation.

8. 7. The hyperbranched dextrin for use according to claim 6, characterized in that the skin inflammation is induced by skin irritation, skin corrosion, skin inflammation of endogenous origin, or a combination of these causes.

9. 8. The hyper-branched dextrin for use according to claim 7, characterized in that the inflammation of the mucous membrane is induced by ingredients contained in a cosmetic, dermocosmetic, dermatological, pharmaceutical, medical, veterinary or household composition or by mechanical insult.

10. 9. The hyper-branched dextrin for use according to claim 8, characterized in that the at least one symptom or skin irritation or skin corrosion or skin inflammation is induced by at least one of the conditions selected from infectious agents, chemicals, ingredients contained in cosmetic, dermatological, pharmaceutical, veterinary, detergent or household compositions, mechanical insults, environmental agents, thermal insults, food and beverages.

11. 9. The hyperbranched dextrin for use according to claim 8, characterized in that the skin irritation is selected from cumulative irritant contact dermatitis, acute irritant contact dermatitis, and phototoxic dermatitis.

12. 7. The hyperbranched dextrin for use according to claim 6, wherein the skin inflammation is induced by a dermatological pathology involving an inflammatory process.

13. The hyperbranched dextrin for use according to claim 12, characterized in that the pathology is selected from erythema, psoriasis, skin atopy, atopic dermatitis, immediate hypersensitivity type allergic reaction, delayed hypersensitivity type allergic reaction, post-inflammatory pigmentation, immune dermatoses, solar elastosis, alopecia areata, vitiligo, systemic lupus erythematosus, pemphigus vulgaris, dystrophic epidermolysis bullosa, and autoimmune leukoderma, erythema, etc.

14. A hyperbranched dextrin for use as described in claim 7, wherein the mucosal inflammation is induced by a lesion involving an inflammatory process.

15. 1. A hyper-branched dextrin for preventing or reducing or eliminating the irritating effect of an ingredient contained in a cosmetic or dermatological, medical, veterinary, detergent or household composition, the hyper-branched dextrin having, relative to the total of 1,2, 1,3, 1,4 and 1,6 bonds: - up to 90% 1,4 glucosidic bonds, - Hyperbranched dextran, characterized in that it contains at least 5% 1,6 glycosidic bonds. The use of Trin.

16. The hyperbranched dextrin is - at least 5%, preferentially at least 10%, more preferentially at least 12% and most preferentially at least 15% 1,6 glucosidic bonds relative to said total of 1,2, 1,3, 1,4 and 1,6 bonds; at most 70%, preferentially at most 60% and most preferentially at most 50% of 1,4 glucosidic bonds relative to said total of 1,2, 1,3, 1,4 and 1,6 bonds, - at least 1%, preferentially at least 5%, more preferentially at least 10% and most preferentially at least 20% of 1,3 glucosidic bonds relative to said total of 1,2, 1,3, 1,4 and 1,6 bonds; Use of hyperbranched dextrins according to claim 15, characterized in that they have at least 1%, preferentially at least 5%, more preferentially at least 10% and most preferentially at least 20% of 1,2 glucosidic bonds relative to said sum of 1,2, 1,3, 1,4 and 1,6.

17. The hyperbranched dextrin is - 42 to 50% 1,4 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; - from 5% to 40% 1,6 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; - from 1 to 20% of 1,3 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; Use of hyperbranched dextrins according to claim 15, characterized in that they have from 1 to 20% of 1,2 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds.

18. 16. Use of hyper-branched dextrins according to claim 15, characterized in that the ingredients are selected from surfactants, fragrances, solvents, preservatives, acids, bases and detergents.

19. A hyperbranched dextrin in a dermatologically acceptable medium, said hyperbranched dextrin having, relative to the sum of 1,2, 1,3, 1,4, and 1,6 bonds: - up to 90% 1,4 glucosidic bonds, at least 5% 1,6 glucosidic bonds, Dermatological composition comprising hyperbranched dextrins, preferentially hyperbranched and hydrogenated dextrins, characterized in that it comprises

20. The hyperbranched dextrin is - at least 5%, preferentially at least 10%, more preferentially at least 12% and most preferentially at least 15% 1,6 glucosidic bonds relative to said total of 1,2, 1,3, 1,4 and 1,6 bonds; at most 70%, preferentially at most 60% and most preferentially at most 50% of 1,4 glucosidic bonds relative to said total of 1,2, 1,3, 1,4 and 1,6 bonds, - at least 1%, preferentially at least 5%, more preferentially at least 10% and most preferentially at least 20% of 1,3 glucosidic bonds relative to said total of 1,2, 1,3, 1,4 and 1,6 bonds; Dermatological composition according to claim 19, characterized in that it has at least 1%, preferentially at least 5%, more preferentially at least 10% and most preferentially at least 20% of 1,2 glucosidic bonds relative to said sum of 1,2, 1,3, 1,4 and 1,6.

21. The hyperbranched dextrin is - 42-50% 1,4 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; - 5% to 40% 1,6 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; - 1-20% 1,3 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds; Dermatological composition according to claim 19, characterized in that it has from 1 to 20% of 1,2 glucosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds.

Images